HQH abrdn Healthcare Investors

 

 

	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB APPROVAL
		OMB Number:  3235-0582
		Expires:  July 31, 2024
		Estimated average burden
		hours per response........4

 

FORM N-PX

 

ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY

 

Investment Company Act file number  811-04889

 

Tekla Healthcare Investors

(Exact name of registrant as specified in charter)

 

100 Federal Street, 19th Floor, Boston, MA		02110
(Address of principal executive offices)		(Zip code)

 

Laura Woodward

Tekla Healthcare Investors

100 Federal Street, 19^th Floor, Boston MA 02110

(Name and address of agent for service)

 

Registrant’s telephone number, including area code:  617-772-8500

 

Date of fiscal year end:  September 30

 

Date of reporting period:  7/1/22-6/30/23

 

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, not later than August 31 of each year, containing the registrant’s proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

 

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

 

 

Item 1. Proxy Voting Record.

 

 

Vote Summary

 

 

ABBOTT LABORATORIES

 

Security	002824100	Meeting Type	Annual
Ticker Symbol	ABT	Meeting Date	28-Apr-2023
Record Date	01-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: R. J. Alpern		Management		For		For
1b.		Election of Director: C. Babineaux-Fontenot		Management		For		For
1c.		Election of Director: S. E. Blount		Management		For		For
1d.		Election of Director: R. B. Ford		Management		For		For
1e.		Election of Director: P. Gonzalez		Management		For		For
1f.		Election of Director: M. A. Kumbier		Management		For		For
1g.		Election of Director: D. W. McDew		Management		For		For
1h.		Election of Director: N. McKinstry		Management		For		For
1i.		Election of Director: M. G. O'Grady		Management		For		For
1j.		Election of Director: M. F. Roman		Management		For		For
1k.		Election of Director: D. J. Starks		Management		For		For
1l.		Election of Director: J. G. Stratton		Management		For		For
2.		Ratification of Ernst & Young LLP As Auditors		Management		For		For
3.		Say on Pay - An Advisory Vote on the Approval of Executive Compensation		Management		For		For
4.		Say When on Pay - An Advisory Vote on the Approval of the Frequency of Shareholder Votes on Executive Compensation		Management		1 Year		For
5.		Shareholder Proposal - Special Shareholder Meeting Threshold		Shareholder		Against		For
6.		Shareholder Proposal - Independent Board Chairman		Shareholder		Against		For
7.		Shareholder Proposal - Lobbying Disclosure		Shareholder		Against		For
8.		Shareholder Proposal - Incentive Compensation		Shareholder		Against		For

 

 

ABBVIE INC.

 

Security	00287Y109	Meeting Type	Annual
Ticker Symbol	ABBV	Meeting Date	05-May-2023
Record Date	06-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Class II Director: Robert J. Alpern		Management		For		For
1b.		Election of Class II Director: Melody B. Meyer		Management		For		For
1c.		Election of Class II Director: Frederick H. Waddell		Management		For		For
2.		Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2023.		Management		For		For
3.		Say on Pay - An advisory vote on the approval of executive compensation.		Management		For		For
4.		Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting.		Management		For		For
5.		Stockholder Proposal - to Implement Simple Majority Vote.		Shareholder		Against		For
6.		Stockholder Proposal - to Issue an Annual Report on Political Spending.		Shareholder		Against		For
7.		Stockholder Proposal - to Issue an Annual Report on Lobbying.		Shareholder		Against		For
8.		Stockholder Proposal - to Issue a Report on Patent Process.		Shareholder		Against		For

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

 

Security	00650F109	Meeting Type	Annual
Ticker Symbol	ADPT	Meeting Date	09-Jun-2023
Record Date	12-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		To elect Class I director nominee to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2026 annual meeting of shareholders: Katey Owen, PhD		Management		For		For
1.2		To elect Class I director nominee to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2026 annual meeting of shareholders: Robert Hershberg, PhD, MD		Management		For		For
2.		To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement.		Management		For		For
3.		To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023.		Management		For		For

 

 

AFFIMED N.V

 

Security	N01045108	Meeting Type	Annual
Ticker Symbol	AFMD	Meeting Date	21-Jun-2023
Record Date	24-May-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
3.		Adoption of the Statutory Annual Accounts for the financial year 2022		Management		For		For
4.		Advisory vote (non-binding) on Executive Compensation		Management		For		For
5.		Discharge of the managing directors for their management during the financial year 2022		Management		For		For
6.		Discharge of the supervisory directors for their supervision during the financial year 2022		Management		For		For
7.		Amendment of the Remuneration Policy for the Supervisory Board		Management		For		For
8a.		Reappointment of Dr. Adi Hoess as a managing director		Management		For		For
8b.		Reappointment of Dr. Wolfgang Fischer as a managing director		Management		For		For
8c.		Reappointment of Mr. Angus Smith as a managing director		Management		For		For
8d.		Reappointment of Dr. Arndt Schottelius as a managing director		Management		For		For
8e.		Reappointment of Dr. Andreas Harstrick as a managing director		Management		For		For
9a.		Reappointment of Dr. Thomas Hecht as a supervisory director		Management		For		For
9b.		Reappointment of Mr. Harry Welten as a supervisory director		Management		For		For
9c.		Reappointment of Dr. Annalisa M. Jenkins as a supervisory director		Management		For		For
9d.		Appointment of Dr. Constanze Ulmer-Eilfort as a supervisory director		Management		For		For
10.		Reverse stock split and amendment of the articles of association		Management		For		For
11.		Authorization to acquire shares		Management		For		For
12.		Appointment of the auditor for the financial year 2023		Management		For		For

 

 

ALKERMES PLC

 

Security	G01767105	Meeting Type	Contested-Annual
Ticker Symbol	ALKS	Meeting Date	29-Jun-2023
Record Date	17-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1A.		BOARD NOMINEE: Emily Peterson Alva		Management		For		For
1B.		BOARD NOMINEE: Shane M. Cooke		Management		For		For
1C.		BOARD NOMINEE: Richard B. Gaynor, M.D.		Management		For		For
1D.		BOARD NOMINEE: Cato T. Laurencin, M.D., Ph.D.		Management		For		For
1E.		BOARD NOMINEE: Brian P. McKeon		Management		For		For
1F.		BOARD NOMINEE: Richard F. Pops		Management		For		For
1G.		BOARD NOMINEE: Christopher I. Wright, M.D., Ph.D.		Management		For		For
1H.		SARISSA NOMINEE: Patrice Bonfiglio		Management		Withheld		For
1I.		SARISSA NOMINEE: Alexander Denner, Ph.D.		Management		Withheld		For
1J.		SARISSA NOMINEE: Sarah J. Schlesinger, M.D.		Management		Withheld		For
2.		To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.		Management		For		For
3.		To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration.		Management		For		For
4.		To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.		Management		For		For
5.		To renew Board authority to allot and issue shares under Irish law.		Management		For		For
6.		To renew Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law.		Management		For		For

 

 

ALNYLAM PHARMACEUTICALS, INC.

 

Security	02043Q107	Meeting Type	Annual
Ticker Symbol	ALNY	Meeting Date	18-May-2023
Record Date	24-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Class I Director: Michael W. Bonney		Management		For		For
1b.		Election of Class I Director: Yvonne L. Greenstreet, MBChB, MBA		Management		For		For
1c.		Election of Class I Director: Phillip A. Sharp, Ph.D.		Management		For		For
1d.		Election of Class I Director: Elliott Sigal, M.D., Ph.D.		Management		For		For
2		To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.		Management		For		For
3.		To recommend, in a non-binding advisory vote, the frequency of advisory stockholder votes on executive compensation.		Management		1 Year		For
4.		To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2023.		Management		For		For

 

AMEDISYS, INC.

 

Security	023436108	Meeting Type	Annual
Ticker Symbol	AMED	Meeting Date	08-Jun-2023
Record Date	11-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Richard M. Ashworth				For		For
		2	Vickie L. Capps				For		For
		3	Molly J. Coye, MD				For		For
		4	Julie D. Klapstein				For		For
		5	Teresa L. Kline				For		For
		6	Paul B. Kusserow				For		For
		7	Bruce D. Perkins				For		For
		8	Jeffery A. Rideout, MD				For		For
		9	Ivanetta Davis Samuels				For		For
2.		To ratify the appointment of KPMG LLP as the Company's independent registered public accountants for the fiscal year ending December 31, 2023.			Management		For		For
3.		To approve, on an advisory (non-binding) basis, the compensation paid to the Company's Named Executive Officers, as set forth in the Company's 2023 Proxy Statement ("Say on Pay" Vote).			Management		For		For
4.		To approve, on an advisory (non-binding) basis, the frequency of future stockholder Say on Pay Votes.			Management		1 Year		For

 

 

AMGEN INC.

 

Security	031162100	Meeting Type	Annual
Ticker Symbol	AMGN	Meeting Date	19-May-2023
Record Date	20-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Wanda M. Austin		Management		For		For
1b.		Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Robert A. Bradway		Management		For		For
1c.		Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Michael V. Drake		Management		For		For
1d.		Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Brian J. Druker		Management		For		For
1e.		Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Robert A. Eckert		Management		For		For
1f.		Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Greg C. Garland		Management		For		For
1g.		Election of Director for a term of office expiring at the 2024 annual meeting: Mr. Charles M. Holley, Jr.		Management		For		For
1h.		Election of Director for a term of office expiring at the 2024 annual meeting: Dr. S. Omar Ishrak		Management		For		For
1i.		Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Tyler Jacks		Management		For		For
1j.		Election of Director for a term of office expiring at the 2024 annual meeting: Ms. Ellen J. Kullman		Management		For		For
1k.		Election of Director for a term of office expiring at the 2024 annual meeting: Ms. Amy E. Miles		Management		For		For
1l.		Election of Director for a term of office expiring at the 2024 annual meeting: Dr. Ronald D. Sugar		Management		For		For
1m.		Election of Director for a term of office expiring at the 2024 annual meeting: Dr. R. Sanders Williams		Management		For		For
2.		Advisory vote on the frequency of future stockholder advisory votes to approve executive compensation.		Management		1 Year		For
3.		Advisory vote to approve our executive compensation.		Management		For		For
4.		To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2023.		Management		For		For

 

 

AMOLYT PHARMA

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	21-Jun-2023
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Approval of the company’s 2022 financials and earnings, discharge of the President for the performance of his duties during the past fiscal year		Management		For		For
2.		Approval of amendment No. 1 dated November 13, 2022 and the amendment No. 2 dated January 6, 2023 to the service agreement entered into on July 25, 2019 between the Company and Tab Consulting, of which Mr. Thierry Abribat is chairman, the terms of which are described in the special report of the Statutory Auditor		Management		For		For
3.		Approval of amendment No.2 dated April 7, 2022 and the amendment No. 3 dated March 8, 2023 to the consulting agreement entered into on May 6, 2020 between the Company and Stone Atlanta Estates LLC (formerly Stone Sunny Isles, Inc.), of which Mr. Pierre Legault is president, the terms of which are described in the special report of the Statutory Auditor		Management		For		For
4.		Approval of amendment No.1 dated January 6, 2023 to the indemnification agreement entered into on June 3, 2020 between the Company and Mr. Pierre Legault, the terms of which are described in the special report of the Statutory Auditor.		Management		For		For
5.		Reappointment of Pierre Legault as a member of the Board of Directors		Management		For		For
6.		Approval of the 2023-1 stock option plan adopted by the President on March 1, 2023		Management		For		For

 

AMPHIVENA THERAPEUTICS, INC.

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	26-Sep-2022
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		General Assignment		Management		For		For
2.		Assignment Amendment		Management		For		For

 

APELLIS PHARMACEUTICALS INC.

 

Security	03753U106	Meeting Type	Annual
Ticker Symbol	APLS	Meeting Date	01-Jun-2023
Record Date	03-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Class III Director to hold office until the 2026 annual meeting: Gerald Chan		Management		For		For
1.2		Election of Class III Director to hold office until the 2026 annual meeting: Cedric Francois		Management		For		For
2.		To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For
3.		To approve an advisory vote on executive compensation.		Management		For		For

 

 

ARCUTIS BIOTHERAPEUTICS, INC.

 

Security	03969K108	Meeting Type	Annual
Ticker Symbol	ARQT	Meeting Date	31-May-2023
Record Date	03-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Class III Director to hold office until the 2026 Annual Meeting: Patrick J. Heron		Management		For		For
1b.		Election of Class III Director to hold office until the 2026 Annual Meeting: Neha Krishnamohan		Management		For		For
1c.		Election of Class III Director to hold office until the 2026 Annual Meeting: Todd Franklin Watanabe		Management		For		For
2.		To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.		Management		For		For
3.		To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.		Management		For		For

 

ARGENX SE

 

Security	04016X101	Meeting Type	Special
Ticker Symbol	ARGX	Meeting Date	08-Sep-2022
Record Date	02-Aug-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
2.		Appointment of Camilla Sylvest as non-executive director to the board of directors of the Company		Management		For

 

ARGENX SE

 

Security	04016X101	Meeting Type	Special
Ticker Symbol	ARGX	Meeting Date	12-Dec-2022
Record Date	08-Nov-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
2.		Appointment of Ana Cespedes as non-executive director to the board of directors of the Company		Management		Abstain

 

 

ARGENX SE

 

Security	04016X101	Meeting Type	Annual
Ticker Symbol	ARGX	Meeting Date	02-May-2023
Record Date	04-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
3.		Advisory vote to approve the 2022 remuneration report.		Management		For
4b.		Adoption of the 2022 annual accounts.		Management		For
4d.		Allocation of losses of the Company in the financial year 2021 to the retained earnings of the Company.		Management		For
4e.		Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2022.		Management		For
5.		Proposal to re-appoint Don deBethizy as non-executive director for a term of two years.		Management		For
6.		Authorization of the board of directors to issue shares and grant rights to subscribe for shares in the share capital of the Company up to a maximum of 10% of the outstanding capital at the date of the general meeting, for a period of 18 months from the annual general meeting and to limit or exclude statutory pre-emptive rights, if any.		Management		For
7.		Appointment of Deloitte Accountants B.V. as statutory auditor for the 2023 financial year.		Management		For

 

ARISTEA THERAPEUTICS, INC.

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	7-Jul-2022
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Appoint Independent director		Management		For		For

 

ARISTEA THERAPEUTICS, INC.

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	7-Jul-2022
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Appoint Series A director		Management		For		For

 

 

ARKUDA THERAPEUTICS, INC.

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	19-Dec-2022
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Second Tranche Closing under Series B Preferred Stock Purchase Agreement		Management		For		For

 

ARKUDA THERAPEUTICS, INC.

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	13-Apr-2023
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Amendment No. 1 to amended and restated voting agreement and stockholder consent		Management		For		For

 

ARROWHEAD PHARMACEUTICALS, INC.

 

Security	04280A100	Meeting Type	Annual
Ticker Symbol	ARWR	Meeting Date	16-Mar-2023
Record Date	20-Jan-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Douglass Given		Management		For		For
1b.		Election of Director: Michael S. Perry		Management		For		For
1c.		Election of Director: Christopher Anzalone		Management		For		For
1d.		Election of Director: Marianne De Backer		Management		For		For
1e.		Election of Director: Mauro Ferrari		Management		For		For
1f.		Election of Director: Adeoye Olukotun		Management		For		For
1g.		Election of Director: William Waddill		Management		For		For
1h.		Election of Director: Victoria Vakiener		Management		For		For
2.		Advisory Vote to Approve Executive Compensation.		Management		For		For
3.		Approval of Amendment to Arrowhead Pharmaceuticals, Inc.'s Amended and Restated Certificate Of Incorporation To Increase The Number Of Authorized Shares Of Common Stock.		Management		For		For
4.		To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2023.		Management		For		For

 

 

ASCENDIS PHARMA A/S

 

Security	04351P101	Meeting Type	Special
Ticker Symbol	ASND	Meeting Date	09-Sep-2022
Record Date	02-Aug-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		The Board of Directors proposes that attorney-at-law Lars Lüthjohan is elected as chairman of the general meeting.		Management		For		For
2a.		Election of Class I, Director for a term expiring at the annual general meeting to be held in 2023: William Carl Fairey Jr		Management		For		For
2b.		Election of Class I, Director for a term expiring at the annual general meeting to be held in 2023: Siham Imani		Management		For		For
3.		The board of directors proposes to authorize the chairman of the meeting (with a right of substitution) on behalf of the Company to apply the Danish Business Authority for registration of the resolution passed and in this connection to make any such amendments and supplements to the application and the resolution, including the Company's articles of association and these minutes of the general meeting, that may be required as a condition for registration.		Management		For		For

 

ASCENDIS PHARMA A/S

 

Security	04351P101	Meeting Type	Annual
Ticker Symbol	ASND	Meeting Date	30-May-2023
Record Date	21-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		The Board of Directors proposes that attorney-at-law Lars Lüthjohan is elected as chairman of the general meeting.		Management		For		For
2.		Chairman of the Board, Albert Cha, and Chief Executive Officer, Jan Møller Mikkelsen or Chief Legal Officer, Michael Wolff Jensen will report on the Company's activities for the year ended December 31, 2022.		Management		For		For
3.		The Board of Directors recommends that the audited annual report will be adopted and that a resolution will be passed to discharge the Board of Directors and Management from liability.		Management		For		For
4.		The Board of Directors proposes that the consolidated loss for the year of EUR 583.2 million be carried forward to next year through recognition in accumulated deficit.		Management		For		For
5a.		Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: Jan Møller Mikkelsen		Management		For		For
5b.		Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: Lisa Morrison		Management		For		For
5c.		Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: William Carl Fairey Jr		Management		For		For
5d.		Re-Election of class I Director for a term expiring at the annual general meeting to be held in 2025: Siham Imani		Management		For		For
6.		The Board of Directors proposes that Deloitte Statsautoriseret Revisionspartnerselskab be re-appointed as the Company's auditor.		Management		For		For
7.		Proposal from the Board of Directors The Board of Directors proposes that the following authorization is adopted: The Board of Directors is authorized, in accordance with the Danish Companies Act, Section 198, during the period until 29 May 2028 on one or more occasions to purchase up to nominal DKK 1,000,000 shares or American Depositary Shares representing a corresponding amount of shares in the Company as treasury shares. The minimum price per share shall be DKK 1 and the maximum price per share shall not exceed the market price.		Management		For		For

 

 

ASTRAZENECA PLC

 

Security	046353108	Meeting Type	Annual
Ticker Symbol	AZN	Meeting Date	27-Apr-2023
Record Date	10-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022		Management		For		For
2.		To confirm dividends		Management		For		For
3.		To reappoint PricewaterhouseCoopers LLP as Auditor		Management		For		For
4.		To authorise the Directors to agree the remuneration of the Auditor		Management		For		For
5a.		Re-election of Director: Michel Demaré		Management		For		For
5b.		Re-election of Director: Pascal Soriot		Management		For		For
5c.		Re-election of Director: Aradhana Sarin		Management		For		For
5d.		Re-election of Director: Philip Broadley		Management		For		For
5e.		Re-election of Director: Euan Ashley		Management		For		For
5f.		Re-election of Director: Deborah DiSanzo		Management		For		For
5g.		Re-election of Director: Diana Layfield		Management		For		For
5h.		Re-election of Director: Sheri McCoy		Management		For		For
5i.		Re-election of Director: Tony Mok		Management		For		For
5j.		Re-election of Director: Nazneen Rahman		Management		For		For
5k.		Re-election of Director: Andreas Rummelt		Management		For		For
5l.		Re-election of Director: Marcus Wallenberg		Management		For		For
6.		To approve the Annual Report on Remuneration for the year ended 31 December 2022		Management		For		For
7.		To authorise limited political donations		Management		For		For
8.		To authorise the Directors to allot shares		Management		For		For
9.		To authorise the Directors to disapply pre-emption rights (Special Resolution)		Management		For		For
10.		To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments (Special Resolution)		Management		For		For
11.		To authorise the Company to purchase its own shares (Special Resolution)		Management		For		For
12.		To reduce the notice period for general meetings (Special Resolution)		Management		For		For
13.		To adopt new Articles of Association (Special Resolution)		Management		For		For

 

 

ASTRAZENECA PLC

 

Security	046353108	Meeting Type	Annual
Ticker Symbol	AZN	Meeting Date	27-Apr-2023
Record Date	04-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022		Management		For		For
2.		To confirm dividends		Management		For		For
3.		To reappoint PricewaterhouseCoopers LLP as Auditor		Management		For		For
4.		To authorise the Directors to agree the remuneration of the Auditor		Management		For		For
5a.		Re-election of Director: Michel Demaré		Management		For		For
5b.		Re-election of Director: Pascal Soriot		Management		For		For
5c.		Re-election of Director: Aradhana Sarin		Management		For		For
5d.		Re-election of Director: Philip Broadley		Management		For		For
5e.		Re-election of Director: Euan Ashley		Management		For		For
5f.		Re-election of Director: Deborah DiSanzo		Management		For		For
5g.		Re-election of Director: Diana Layfield		Management		For		For
5h.		Re-election of Director: Sheri McCoy		Management		For		For
5i.		Re-election of Director: Tony Mok		Management		For		For
5j.		Re-election of Director: Nazneen Rahman		Management		For		For
5k.		Re-election of Director: Andreas Rummelt		Management		For		For
5l.		Re-election of Director: Marcus Wallenberg		Management		For		For
6.		To approve the Annual Report on Remuneration for the year ended 31 December 2022		Management		For		For
7.		To authorise limited political donations		Management		For		For
8.		To authorise the Directors to allot shares		Management		For		For
9.		To authorise the Directors to disapply pre-emption rights (Special Resolution)		Management		For		For
10.		To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments (Special Resolution)		Management		For		For
11.		To authorise the Company to purchase its own shares (Special Resolution)		Management		For		For
12.		To reduce the notice period for general meetings (Special Resolution)		Management		For		For
13.		To adopt new Articles of Association (Special Resolution)		Management		For		For

 

 

BIOCRYST PHARMACEUTICALS, INC.

 

Security	09058V103	Meeting Type	Annual
Ticker Symbol	BCRX	Meeting Date	13-Jun-2023
Record Date	17-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	George B. Abercrombie				For		For
		2	Theresa M. Heggie				For		For
		3	Amy E. McKee, M.D.				For		For
		4	Jon P. Stonehouse				For		For
2.		To ratify the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2023.			Management		For		For
3.		To approve, on an advisory basis, the Company's executive compensation.			Management		For		For
4.		To provide an advisory vote on the frequency of future advisory votes on the Company's executive compensation.			Management		1 Year		For
5.		To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance under the Stock Incentive Plan by 7,000,000 shares.			Management		For		For

 

 

BIOGEN INC.

 

Security	09062X103	Meeting Type	Annual
Ticker Symbol	BIIB	Meeting Date	26-Jun-2023
Record Date	20-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Not Applicable		Management		For		For
1b.		Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Caroline D. Dorsa		Management		For		For
1c.		Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Maria C. Freire		Management		For		For
1d.		Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: William A. Hawkins		Management		For		For
1e.		Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Not Applicable		Management		For		For
1f.		Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Jesus B. Mantas		Management		For		For
1g.		Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Not Applicable		Management		For		For
1h.		Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Eric K. Rowinsky		Management		For		For
1i.		Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Stephen A. Sherwin		Management		For		For
1j.		Election of Director to serve for a one-year term extending until the 2024 Annual Meeting: Christopher A. Viehbacher		Management		For		For
2.		To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For
3.		Say on Pay - To approve an advisory vote on executive compensation.		Management		For		For
4.		Say When on Pay - To approve an advisory vote on the frequency of the advisory vote on executive compensation.		Management		1 Year		For
5.		To elect Susan Langer as a director		Management

 

 

BIOHAVEN LTD

 

Security	G1110E107	Meeting Type	Annual
Ticker Symbol	BHVN	Meeting Date	02-May-2023
Record Date	06-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director for a term expiring at the 2026 Annual Meeting of shareholders: Michael T. Heffernan		Management		For		For
1b.		Election of Director for a term expiring at the 2026 Annual Meeting of shareholders: Irina A. Antonijevic, M.D., Ph.D.		Management		For		For
1c.		Election of Director for a term expiring at the 2026 Annual Meeting of shareholders: Robert J. Hugin		Management		For		For
2.		Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2023.		Management		For		For

 

BIOHAVEN PHARMACEUTICAL HLDG CO LTD

 

Security	G11196105	Meeting Type	Special
Ticker Symbol	BHVN	Meeting Date	29-Sep-2022
Record Date	29-Aug-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		To adopt (i) the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven"), Pfizer Inc. & Bulldog (BVI) Ltd., (ii) the form of Plan of Reverse Triangular Merger & form of Plan of Forward Triangular Merger (together, the "Plan of Merger") & (iii) Separation & Distribution Agreement, dated as of May 9, 2022 ("Distribution Agreement"), by and between Biohaven & Biohaven Research Ltd. ("SpinCo"), in each case, as they may be amended from time to time.		Management		For		For
2.		To approve, by non-binding, advisory vote, certain compensatory arrangements for Biohaven's named executive officers in connection with the acquisition by Pfizer of Biohaven and the distribution to Biohaven's shareholders of all of the issued and outstanding common shares of SpinCo.		Management		For		For
3.		To adjourn the Special Meeting, if necessary, desirable or appropriate, to solicit additional proxies if, at the time of the Special Meeting, there are an insufficient number of votes to adopt the Merger Agreement, the Plan of Merger and the Distribution Agreement.		Management		For		For

 

 

BIOMARIN PHARMACEUTICAL INC.

 

Security	09061G101	Meeting Type	Annual
Ticker Symbol	BMRN	Meeting Date	23-May-2023
Record Date	27-Mar-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Mark J. Alles				For		For
		2	Elizabeth M. Anderson				For		For
		3	Jean-Jacques Bienaimé				For		For
		4	Willard Dere				For		For
		5	Elaine J. Heron				For		For
		6	Maykin Ho				For		For
		7	Robert J. Hombach				For		For
		8	V. Bryan Lawlis				For		For
		9	Richard A. Meier				For		For
		10	David E.I. Pyott				For		For
		11	Dennis J. Slamon				For		For
2.		To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023.			Management		For		For
3.		To approve, on an advisory basis, the frequency of the stockholders' approval, on an advisory basis, of the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.			Management		1 Year		For
4.		To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.			Management		For		For
5.		To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.			Management		For		For

 

 

BIONTECH SE

 

Security	09075V102	Meeting Type	Annual
Ticker Symbol	BNTX	Meeting Date	25-May-2023
Record Date	17-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
2		Resolution on the appropriation of the balance sheet profit for the financial year 2021.		Management		For		For
3		Resolution on the appropriation of the balance sheet profit for the financial year 2022.		Management		For		For
4		Resolution on the approval of the actions of the Management Board.		Management		For		For
5		Resolution on the approval of the actions of the Supervisory Board.		Management		For		For
6		Resolution on the appointment of the auditor of the financial statements and the auditor of the consolidated financial statements for the financial year 2023 as well as the auditor for a possible audit or audit review of interim reports.		Management		For		For
7		Resolution on the approval of the remuneration report.		Management		For		For
8.1		Election to the Supervisory Board: Baroness Nicola Blackwood		Management		For		For
8.2		Election to the Supervisory Board: Ulrich Wandschneider, Ph.D.		Management		For		For
8.3		Election to the Supervisory Board: Mr. Michael Motschmann		Management		For		For
9		Resolution on the Amendment to Sec. 16 para. 5 of the Articles of Association to authorise the Management Board to provide for the holding of a virtual Annual General Meeting.		Management		For		For
10		Resolution on the Amendment to Sec. 16 para. 4 of the Articles of Association on the participation of members of the Supervisory Board in the Annual General Meeting by means of video and audio transmission.		Management		For		For
11a		Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Idar-Oberstein Services GmbH as dependent company.		Management		For		For
11b		Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and NT Security and Services GmbH as dependent company.		Management		For		For
11c		Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech BioNTainer Holding GmbH as dependent company.		Management		For		For
11d		Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Individualized mRNA Manufacturing GmbH as dependent company.		Management		For		For

 

 

BLACK DIAMOND THERAPEUTICS, INC.

 

Security	09203E105	Meeting Type	Annual
Ticker Symbol	BDTX	Meeting Date	16-May-2023
Record Date	20-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Class III Director: David M. Epstein		Management		For		For
1b.		Election of Class III Director: Wendy L. Dixon		Management		For		For
1c.		Election of Class III Director: Kapil Dhingra		Management		For		For
2.		To ratify the appointment of PricewaterhouseCoopers LLP as Black Diamond Therapeutics, Inc.'s independent registered accounting firm for the fiscal year ending December 31, 2023.		Management		For		For

 

BLUEPRINT MEDICINES CORPORATION

 

Security	09627Y109	Meeting Type	Annual
Ticker Symbol	BPMC	Meeting Date	21-Jun-2023
Record Date	24-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Alexis Borisy				For		For
		2	Lonnel Coats				For		For
		3	Kathryn Haviland				For		For
2.		Approve a non-binding, advisory vote on the compensation paid to our named executive officers.			Management		For		For
3.		Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.			Management		For		For

 

 

BOSTON SCIENTIFIC CORPORATION

 

Security	101137107	Meeting Type	Annual
Ticker Symbol	BSX	Meeting Date	04-May-2023
Record Date	10-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Nelda J. Connors		Management		For		For
1b.		Election of Director: Charles J. Dockendorff		Management		For		For
1c.		Election of Director: Yoshiaki Fujimori		Management		For		For
1d.		Election of Director: Edward J. Ludwig		Management		For		For
1e.		Election of Director: Michael F. Mahoney		Management		For		For
1f.		Election of Director: David J. Roux		Management		For		For
1g.		Election of Director: John E. Sununu		Management		For		For
1h.		Election of Director: David S. Wichmann		Management		For		For
1i.		Election of Director: Ellen M. Zane		Management		For		For
2.		To approve, on a non-binding, advisory basis, the compensation of our named executive officers.		Management		For		For
3.		To approve, on a non-binding, advisory basis, the frequency of future advisory votes on the compensation of our named executive officers.		Management		1 Year		For
4.		To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2023 fiscal year.		Management		For		For

 

BRIDGEBIO PHARMA INC.

 

Security	10806X102	Meeting Type	Annual
Ticker Symbol	BBIO	Meeting Date	21-Jun-2023
Record Date	24-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	James C. Momtazee				For		For
		2	Frank McCormick, Ph.D.				For		For
		3	Randal W. Scott, Ph.D.				For		For
		4	Hannah A. Valantine MD				For		For
2.		To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.			Management		For		For
3.		To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.			Management		For		For

 

 

BRISTOL-MYERS SQUIBB COMPANY

 

Security	110122108	Meeting Type	Annual
Ticker Symbol	BMY	Meeting Date	02-May-2023
Record Date	13-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1A.		Election of Director: Peter J. Arduini		Management		For		For
1B.		Election of Director: Deepak L. Bhatt, M.D., M.P.H.		Management		For		For
1C.		Election of Director: Giovanni Caforio, M.D.		Management		For		For
1D.		Election of Director: Julia A. Haller, M.D.		Management		For		For
1E.		Election of Director: Manuel Hidalgo Medina, M.D., Ph.D.		Management		For		For
1F.		Election of Director: Paula A. Price		Management		For		For
1G.		Election of Director: Derica W. Rice		Management		For		For
1H.		Election of Director: Theodore R. Samuels		Management		For		For
1I.		Election of Director: Gerald L. Storch		Management		For		For
1J.		Election of Director: Karen H. Vousden, Ph.D.		Management		For		For
1K.		Election of Director: Phyllis R. Yale		Management		For		For
2.		Advisory Vote to Approve the Compensation of our Named Executive Officers.		Management		For		For
3.		Advisory Vote on the Frequency of the Advisory Vote on the Compensation of our Named Executive Officers.		Management		1 Year		For
4.		Ratification of the Appointment of an Independent Registered Public Accounting Firm.		Management		For		For
5.		Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director.		Shareholder		For		Against
6.		Shareholder Proposal on Workplace Non-Discrimination Audit.		Shareholder		Against		For
7.		Shareholder Proposal on Special Shareholder Meeting Improvement.		Shareholder		Against		For

 

 

CARDIOVASCULAR SYSTEMS, INC.

 

Security	141619106	Meeting Type	Special
Ticker Symbol	CSII	Meeting Date	27-Apr-2023
Record Date	14-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		To adopt the Agreement and Plan of Merger, dated February 8, 2023 (such agreement, as it may be amended, modified or supplemented from time to time, the "Merger Agreement"), by and among Cardiovascular Systems, Inc. ("CSI"), Abbott Laboratories ("Abbott"), and Cobra Acquisition Co. ("Merger Sub"). Upon the terms and subject to the conditions of the Merger Agreement, Abbott will acquire CSI via a merger of Merger Sub with and into CSI, with CSI continuing as the surviving corporation and a wholly owned subsidiary of Abbott (the "Merger").		Management		For		For
2.		To approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to CSI's named executive officers that is based on or otherwise relates to the Merger Agreement, the Merger, and the other transactions contemplated by the Merger Agreement.		Management		For		For
3.		To adjourn the Special Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies to approve the proposal to adopt the Merger Agreement if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting.		Management		For		For

 

 

CARIBOU BIOSCIENCES, INC.

 

Security	142038108	Meeting Type	Annual
Ticker Symbol	CRBU	Meeting Date	20-Sep-2022
Record Date	04-Aug-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Class 1 Director: Scott Braunstein, M.D.		Management		For		For
1b.		Election of Class 1 Director: Ran Zheng, M.S.		Management		For		For
2.		Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022		Management		For		For

 

CARIBOU BIOSCIENCES, INC.

 

Security	142038108	Meeting Type	Annual
Ticker Symbol	CRBU	Meeting Date	15-Jun-2023
Record Date	17-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Class II Director: Andrew Guggenhime, M.B.A.		Management		For		For
1b.		Election of Class II Director: David L. Johnson, M.B.A.		Management		For		For
1c.		Election of Class II Director: Nancy Whiting, Pharm.D.		Management		For		For
2.		Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023		Management		For		For

 

 

CEREVEL THERAPEUTICS HOLDINGS, INC.

 

Security	15678U128	Meeting Type	Annual
Ticker Symbol	CERE	Meeting Date	07-Jun-2023
Record Date	10-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Marijn Dekkers		Management		For		For
1.2		Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Deval Patrick		Management		For		For
1.3		Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Norbert Riedel		Management		For		For
1.4		Election of Class III Director for a three-year term expiring at the 2026 Annual Meeting: Gabrielle Sulzberger		Management		For		For
2.		To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement.		Management		For		For
3.		To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023.		Management		For		For

 

CHARLES RIVER LABORATORIES INTL., INC.

 

Security	159864107	Meeting Type	Annual
Ticker Symbol	CRL	Meeting Date	09-May-2023
Record Date	16-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: James C. Foster		Management		For		For
1b.		Election of Director: Nancy C. Andrews		Management		For		For
1c.		Election of Director: Robert Bertolini		Management		For		For
1d.		Election of Director: Deborah T. Kochevar		Management		For		For
1e.		Election of Director: George Llado, Sr.		Management		For		For
1f.		Election of Director: Martin W. Mackay		Management		For		For
1g.		Election of Director: George E. Massaro		Management		For		For
1h.		Election of Director: C. Richard Reese		Management		For		For
1i.		Election of Director: Craig B. Thompson		Management		For		For
1j.		Election of Director: Richard F. Wallman		Management		For		For
1k.		Election of Director: Virginia M. Wilson		Management		For		For
2.		Advisory Approval of 2022 Executive Officer Compensation		Management		For		For
3.		Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation		Management		1 Year		For
4.		Ratification of PricewaterhouseCoopers LLC as independent registered public accounting firm for 2023		Management		For		For
5.		Proposal to publish a report on non-human primates imported by Charles River Laboratories International, Inc.		Management		Against		For

 

 

CHEMOCENTRYX, INC.

 

Security	16383L106	Meeting Type	Special
Ticker Symbol	CCXI	Meeting Date	18-Oct-2022
Record Date	13-Sep-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		To adopt the Agreement and Plan of Merger, dated as of August 3, 2022 (the "Merger Agreement"), by and among ChemoCentryx, Inc. ("ChemoCentryx"), Amgen Inc. ("Amgen") and Carnation Merger Sub, Inc., a wholly owned subsidiary of Amgen ("Merger Sub"), pursuant to which Merger Sub will be merged with and into ChemoCentryx (the "Merger") with ChemoCentryx surviving the Merger as a wholly owned subsidiary of Amgen.		Management		For		For
2.		To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to ChemoCentryx's named executive officers that is based on or otherwise relates to the Merger.		Management		For		For
3.		To approve the adjournment of the Special Meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting.		Management		For		For

 

CHINOOK THERAPEUTICS, INC.

 

Security	16961L106	Meeting Type	Annual
Ticker Symbol	KDNY	Meeting Date	09-Jun-2023
Record Date	17-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Michelle Griffin				For		For
		2	Eric Dobmeier				For		For
2.		Ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.			Management		For		For
3.		Advisory vote on the compensation of the Company's named executive officers.			Management		For		For
4.		Approval of the Company's Amended and Restated Certificate of Incorporation.			Management		For		For
5.		Approval of the Company's Amended and Restated 2015 Equity Incentive Plan.			Management		For		For

 

 

CURASEN THERAPEUTICS, INC.

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	21-Oct-2022
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Amendment To Certificate Of Incorporation		Management		For		For
2.		Series A Preferred Stock Extension Financing		Management		For		For
3.		Waiver of Preemptive Rights		Management		For		For
4.		General Authority and Ratification		Management		For		For

 

CURASEN THERAPEUTICS, INC.

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	3-Jan-2023
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Amendment to Amended and Restated 2016 Equity Incentive Plan		Management		For		For
2.		General Authority and Ratification		Management		For		For

 

CYTOKINETICS, INCORPORATED

 

Security	23282W605	Meeting Type	Annual
Ticker Symbol	CYTK	Meeting Date	10-May-2023
Record Date	21-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Class I Director: Edward M. Kaye, M.D.		Management		For		For
1b.		Election of Class I Director: Wendell Wierenga, Ph.D.		Management		For		For
1c.		Election of Class I Director: Nancy J. Wysenski		Management		For		For
2.		To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to permit the exculpation of the Company's directors.		Management		For		For
3.		To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to permit the exculpation of senior officers of the Company.		Management		For		For
4.		To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For
5.		To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.		Management		For		For
6.		To determine, on an advisory basis, the frequency with which the stockholders of the Company wish to have an advisory vote on the compensation of the named executive officers.		Management		1 Year		For

 

 

DANAHER CORPORATION

 

Security	235851102	Meeting Type	Annual
Ticker Symbol	DHR	Meeting Date	09-May-2023
Record Date	10-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Rainer M. Blair		Management		For		For
1b.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Feroz Dewan		Management		For		For
1c.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Linda Filler		Management		For		For
1d.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Teri List		Management		For		For
1e.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Walter G. Lohr, Jr.		Management		For		For
1f.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Jessica L. Mega, MD, MPH		Management		For		For
1g.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Mitchell P. Rales		Management		For		For
1h.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Steven M. Rales		Management		For		For
1i.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Pardis C. Sabeti, MD, D. PHIL		Management		For		For
1j.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: A. Shane Sanders		Management		For		For
1k.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: John T. Schwieters		Management		For		For
1l.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Alan G. Spoon		Management		For		For
1m.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Raymond C. Stevens, Ph.D		Management		For		For
1n.		Election of Director to hold office until the 2024 Annual Meeting of Shareholders: Elias A. Zerhouni, MD		Management		For		For
2.		To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2023.		Management		For		For
3.		To approve on an advisory basis the Company's named executive officer compensation.		Management		For		For
4.		To hold an advisory vote relating to the frequency of future shareholder advisory votes on the Company's executive officer compensation.		Management		1 Year		For
5.		To act upon a shareholder proposal requesting adoption of a policy separating the chair and CEO roles and requiring an independent Board Chair whenever possible.		Shareholder		For		Against
6.		To act upon a shareholder proposal requesting a report to shareholders on the effectiveness of the Company's diversity, equity and inclusion efforts.		Shareholder		Against		For

 

 

DENALI THERAPEUTICS INC.

 

Security	24823R105	Meeting Type	Annual
Ticker Symbol	DNLI	Meeting Date	01-Jun-2023
Record Date	04-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Jennifer Cook				For		For
		2	David Schenkein, M.D.				For		For
		3	Ryan Watts, Ph.D.				For		For
2.		Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023			Management		For		For
3.		Advisory vote on executive compensation			Management		For		For

 

 

DEXCOM, INC.

 

Security	252131107	Meeting Type	Annual
Ticker Symbol	DXCM	Meeting Date	18-May-2023
Record Date	29-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Director to hold office until our 2024 Annual Meeting: Steven R. Altman		Management		For		For
1.2		Election of Director to hold office until our 2024 Annual Meeting: Richard A. Collins		Management		For		For
1.3		Election of Director to hold office until our 2024 Annual Meeting: Karen Dahut		Management		For		For
1.4		Election of Director to hold office until our 2024 Annual Meeting: Mark G. Foletta		Management		For		For
1.5		Election of Director to hold office until our 2024 Annual Meeting: Barbara E. Kahn		Management		For		For
1.6		Election of Director to hold office until our 2024 Annual Meeting: Kyle Malady		Management		For		For
1.7		Election of Director to hold office until our 2024 Annual Meeting: Eric J. Topol, M.D.		Management		For		For
2.		To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For
3.		To hold a non-binding vote on an advisory resolution to approve executive compensation.		Management		For		For
4.		To recommend a non-binding advisory resolution on the frequency of stockholder votes on executive compensation.		Management		1 Year		For
5.		To hold a non-binding vote on pay equity disclosure.		Management		Against		For

 

DYNACURE

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	10-Oct-2022
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		To approve the Term Sheet and the principle of the Merger subject to the terms and conditions set forth therein; and		Management		For		For
2.		To waive their rights to the liquidation preference under the Shareholders’ Agreement in connection with the contemplated Merger, subject to their replacement by new preference rights as described in the Term Sheet		Management		For		For

 

 

DYNACURE

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	23-Jan-2023
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Merger with Flamingo		Management		For		For

 

EDWARDS LIFESCIENCES CORPORATION

 

Security	28176E108	Meeting Type	Annual
Ticker Symbol	EW	Meeting Date	11-May-2023
Record Date	13-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Director: Kieran T. Gallahue		Management		For		For
1.2		Election of Director: Leslie S. Heisz		Management		For		For
1.3		Election of Director: Paul A. LaViolette		Management		For		For
1.4		Election of Director: Steven R. Loranger		Management		For		For
1.5		Election of Director: Martha H. Marsh		Management		For		For
1.6		Election of Director: Michael A. Mussallem		Management		For		For
1.7		Election of Director: Ramona Sequeira		Management		For		For
1.8		Election of Director: Nicholas J. Valeriani		Management		For		For
1.9		Election of Director: Bernard J. Zovighian		Management		For		For
2.		Advisory Vote to Approve Named Executive Officer Compensation		Management		For		For
3.		Advisory Vote to Approve Frequency of Future Advisory Votes on Named Executive Officer Compensation		Management		1 Year		For
4.		Ratification of Appointment of Independent Registered Public Accounting Firm		Management		For		For
5.		Approval of Amendment of the Certificate of Incorporation to Provide for Exculpation of Officers		Management		For		For
6.		Stockholder Proposal regarding Independent Board Chairman Policy		Shareholder		Against		For

 

 

ELEVANCE HEALTH, INC.

 

Security	036752103	Meeting Type	Annual
Ticker Symbol	ELV	Meeting Date	10-May-2023
Record Date	17-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Gail K. Boudreaux		Management		For		For
1b.		Election of Director: R. Kerry Clark		Management		For		For
1c.		Election of Director: Robert L. Dixon, Jr.		Management		For		For
1d.		Election of Director: Deanna D. Strable		Management		For		For
2.		Advisory vote to approve the compensation of our named executive officers.		Management		For		For
3.		Advisory vote on the frequency of the advisory vote to approve the compensation of our named executive officers.		Management		1 Year		For
4.		To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2023.		Management		For		For
5.		Shareholder proposal to allow shareholders owning 10% or more of our common stock to call a special meeting of shareholders.		Shareholder		Against		For
6.		Shareholder proposal requesting annual reporting from third parties seeking financial support.		Shareholder		Against		For

 

ELI LILLY AND COMPANY

 

Security	532457108	Meeting Type	Annual
Ticker Symbol	LLY	Meeting Date	01-May-2023
Record Date	21-Feb-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director to serve a three-year term: William G. Kaelin, Jr.		Management		For		For
1b.		Election of Director to serve a three-year term: David A. Ricks		Management		For		For
1c.		Election of Director to serve a three-year term: Marschall S. Runge		Management		For		For
1d.		Election of Director to serve a three-year term: Karen Walker		Management		For		For
2.		Approval, on an advisory basis, of the compensation paid to the company's named executive officers.		Management		For		For
3.		Advisory vote on frequency of future advisory votes on named executive officer compensation.		Management		1 Year		For
4.		Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2023.		Management		For		For
5.		Approval of amendments to the company's Articles of Incorporation to eliminate the classified board structure.		Management		For		For
6.		Approval of amendments to the company's Articles of Incorporation to eliminate supermajority voting provisions.		Management		For		For
7.		Shareholder proposal to publish an annual report disclosing lobbying activities.		Shareholder		Against		For
8.		Shareholder proposal to eliminate supermajority voting requirements.		Shareholder		Against		For
9.		Shareholder proposal to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents.		Shareholder		Against		For
10.		Shareholder proposal to report on risks of supporting abortion.		Shareholder		Against		For
11.		Shareholder proposal to disclose lobbying activities and alignment with public policy positions and statements.		Shareholder		Against		For
12.		Shareholder proposal to report on effectiveness of the company's diversity, equity, and inclusion efforts.		Shareholder		Against		For
13.		Shareholder proposal to adopt a policy to require certain third-party organizations to annually report expenditures for political activities before Lilly contributes to an organization.		Shareholder		Against		For

 

 

EXELIXIS, INC.

 

Security	30161Q104	Meeting Type	Contested-Annual
Ticker Symbol	EXEL	Meeting Date	31-May-2023
Record Date	03-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1A.		Company Nominee: Maria C. Freire		Management		For		For
1B.		Company Nominee: Alan M. Garber		Management		For		For
1C.		Company Nominee: Michael M. Morrissey		Management		For		For
1D.		Company Nominee: Stelios Papadopoulos		Management		For		For
1E.		Company Nominee: George Poste		Management		For		For
1F.		Company Nominee: Julie Anne Smith		Management		For		For
1G.		Company Nominee: Lance Willsey		Management		For		For
1H.		Company Nominee: Jacqueline Wright		Management		For		For
1I.		Company Nominee: Jack L. Wyszomierski		Management		For		For
1J.		Company Recommended Farallon-Caligan Nominee: Tomas J. Heyman		Management		For		For
1K.		Company Recommended Farallon-Caligan Nominee: Robert "Bob" Oliver, Jr.		Management		For		For
1L.		Farallon-Caligan Nominee: David E. Johnson		Management		Withheld		*
2.		To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the fiscal year ending December 29, 2023.		Management		For		For
3.		To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the Proxy Statement.		Management		For		For
4.		To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of Exelixis' named executive officers.		Management		1 Year		For

 

 

FLAMINGO THERAPEUTICS, INC

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	28-Mar-2023
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Reports		Management		For		For
2.		Creation of new classes of shares according to the report of the board of directors in accordance with Articles 7:155, 7:179, 7:180 and 7:191 of the Companies and Associations Code		Management		For		For
3.		Issue of new shares by capital increase in cash		Management		For		For
4.		Cancellation and issuance of subscription rights		Management		For		For
5.		Issue of anti-dilutive subscription rights		Management		For		For
6.		Confirmation of the cancellation of all securities or rights giving access to the capital of Dynacure SA in the context of the merger		Management		For		For
7.		Proxies		Management		For		For

 

FLAMINGO THERAPEUTICS, INC

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	19-May-2023
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Acknowledgment of the report of the statutory auditor		Management		For		For
2.		Approval of the annual accounts for the fiscal year ended on 31 December 2022		Management		For		For
3.		Allocation of the results		Management		For		For
4.		Release of liability to the directors and the statutory auditor for the exercise of their mandate during the past fiscal year		Management		For		For

 

 

FUSION PHARMACEUTICALS INC

 

Security	36118A100	Meeting Type	Annual
Ticker Symbol	FUSN	Meeting Date	14-Jun-2023
Record Date	18-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Director to serve until the next annual meeting: Donald Bergstrom, M.D., Ph.D.		Management		For		For
1.2		Election of Director to serve until the next annual meeting: Pablo Cagnoni, M.D.		Management		For		For
1.3		Election of Director to serve until the next annual meeting: Johan Christenson, M.D., Ph.D.		Management		For		For
1.4		Election of Director to serve until the next annual meeting: Barbara Duncan		Management		For		For
1.5		Election of Director to serve until the next annual meeting: Steve Gannon		Management		For		For
1.6		Election of Director to serve until the next annual meeting: Chau Khuong		Management		For		For
1.7		Election of Director to serve until the next annual meeting: Philina Lee, Ph.D.		Management		For		For
1.8		Election of Director to serve until the next annual meeting: Heather Preston, M.D.		Management		For		For
1.9		Election of Director to serve until the next annual meeting: John Valliant, Ph.D.		Management		For		For
2.		To appoint PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For

 

G1 THERAPEUTICS, INC.

 

Security	3621LQ109	Meeting Type	Annual
Ticker Symbol	GTHX	Meeting Date	15-Jun-2023
Record Date	18-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Class III Director: Garry A. Nicholson		Management		For		For
1.2		Election of Class III Director: Mark A. Velleca, M.D., Ph.D.		Management		For		For
1.3		Election of Class III Director: Glenn P. Muir		Management		For		For
2.		An advisory (non-binding) vote to approve executive compensation		Management		For		For
3.		The ratification of the appointment of PricewaterhouseCoopers LLP as G1 Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2023		Management		For		For

 

 

GALERA THERAPEUTICS, INC.

 

Security	36338D108	Meeting Type	Annual
Ticker Symbol	GRTX	Meeting Date	14-Jun-2023
Record Date	21-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Michael Powell, Ph.D.				For		For
		2	Linda West				For		For
2.		To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.			Management		For		For

 

GILEAD SCIENCES, INC.

 

Security	375558103	Meeting Type	Annual
Ticker Symbol	GILD	Meeting Date	03-May-2023
Record Date	15-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Jacqueline K. Barton, Ph.D.		Management		For		For
1b.		Election of Director: Jeffrey A. Bluestone, Ph.D.		Management		For		For
1c.		Election of Director: Sandra J. Horning, M.D.		Management		For		For
1d.		Election of Director: Kelly A. Kramer		Management		For		For
1e.		Election of Director: Kevin E. Lofton		Management		For		For
1f.		Election of Director: Harish Manwani		Management		For		For
1g.		Election of Director: Daniel P. O'Day		Management		For		For
1h.		Election of Director: Javier J. Rodriguez		Management		For		For
1i.		Election of Director: Anthony Welters		Management		For		For
2.		To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For
3.		To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.		Management		For		For
4.		To approve, on an advisory basis, the frequency of future advisory stockholder votes on executive compensation.		Management		1 Year		For
5.		To approve an amendment and restatement of the Gilead Sciences, Inc. Employee Stock Purchase Plan and the Gilead Sciences, Inc. International Employee Stock Purchase Plan.		Management		For		For
6.		To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board implement a process to nominate at least one more candidate than the number of directors to be elected.		Shareholder		Against		For
7.		To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board amend the company governing documents to give street name shares and non-street name shares an equal right to call a special stockholder meeting.		Shareholder		Against		For
8.		To vote on a stockholder proposal, if properly presented at the meeting, requesting a report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents.		Shareholder		Against		For

 

 

GUARDANT HEALTH, INC.

 

Security	40131M109	Meeting Type	Annual
Ticker Symbol	GH	Meeting Date	14-Jun-2023
Record Date	17-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Class II Director: Ian Clark		Management		For		For
1b.		Election of Class II Director: Meghan Joyce		Management		For		For
1c.		Election of Class II Director: Samir Kaul		Management		For		For
2.		Ratification of the appointment of Deloitte & Touche LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2023.		Management		For		For
3.		Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.		Management		For		For

 

HCA HEALTHCARE, INC.

 

Security	40412C101	Meeting Type	Annual
Ticker Symbol	HCA	Meeting Date	19-Apr-2023
Record Date	24-Feb-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Thomas F. Frist III		Management		For		For
1b.		Election of Director: Samuel N. Hazen		Management		For		For
1c.		Election of Director: Meg G. Crofton		Management		For		For
1d.		Election of Director: Robert J. Dennis		Management		For		For
1e.		Election of Director: Nancy-Ann DeParle		Management		For		For
1f.		Election of Director: William R. Frist		Management		For		For
1g.		Election of Director: Hugh F. Johnston		Management		For		For
1h.		Election of Director: Michael W. Michelson		Management		For		For
1i.		Election of Director: Wayne J. Riley, M.D.		Management		For		For
1j.		Election of Director: Andrea B. Smith		Management		For		For
2.		To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023.		Management		For		For
3.		To approve the HCA Healthcare, Inc. 2023 Employee Stock Purchase Plan.		Management		For		For
4.		Advisory vote to approve named executive officer compensation.		Management		For		For
5.		Stockholder proposal, if properly presented at the meeting, regarding political spending disclosure.		Shareholder		Against		For
6.		Stockholder proposal, if properly presented at the meeting, regarding amendment to Patient Safety and Quality of Care Committee charter.		Shareholder		Against		For

 

 

HORIZON THERAPEUTICS PLC

 

Security	G46188101	Meeting Type	Special
Ticker Symbol	HZNP	Meeting Date	24-Feb-2023
Record Date	19-Jan-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Ordinary Resolution to approve the Scheme of Arrangement and authorize the directors of Horizon to take all such actions as they consider necessary or appropriate for carrying the Scheme of Arrangement into effect.		Management		For		For
2.		Special Resolution to amend the articles of association of Horizon so that any Horizon Shares that are issued on or after the Voting Record Time to persons other than Acquirer Sub or its nominee(s) will either be subject to the terms of the Scheme of Arrangement or be immediately and automatically acquired by Acquirer Sub and/or its nominee(s) for the Scheme Consideration.		Management		For		For
3.		Ordinary Resolution to approve, on a non-binding, advisory basis, specified compensatory arrangements between Horizon and its named executive officers relating to the Transaction.		Management		For		For
4.		Ordinary Resolution to approve any motion by the Chairman to adjourn the EGM or any adjournments thereof, to solicit additional proxies in favor of the approval of the resolutions if there are insufficient votes at the time of the EGM to approve resolutions 1 and 2.		Management		For		For

 

HORIZON THERAPEUTICS PLC

 

Security	G46188111	Meeting Type	Special
Ticker Symbol	HZNP	Meeting Date	24-Feb-2023
Record Date	19-Jan-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		That the Scheme of Arrangement in its original form or with or subject to any modification(s), addition(s) or condition(s) approved or imposed by the Irish High Court be agreed to.		Management		For		For

 

 

HUMANA INC.

 

Security	444859102	Meeting Type	Annual
Ticker Symbol	HUM	Meeting Date	20-Apr-2023
Record Date	28-Feb-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a)		Election of Director: Raquel C. Bono, M.D.		Management		For		For
1b)		Election of Director: Bruce D. Broussard		Management		For		For
1c)		Election of Director: Frank A. D'Amelio		Management		For		For
1d)		Election of Director: David T. Feinberg, M.D.		Management		For		For
1e)		Election of Director: Wayne A. I. Frederick, M.D.		Management		For		For
1f)		Election of Director: John W. Garratt		Management		For		For
1g)		Election of Director: Kurt J. Hilzinger		Management		For		For
1h)		Election of Director: Karen W. Katz		Management		For		For
1i)		Election of Director: Marcy S. Klevorn		Management		For		For
1j)		Election of Director: William J. McDonald		Management		For		For
1k)		Election of Director: Jorge S. Mesquita		Management		For		For
1l)		Election of Director: Brad D. Smith		Management		For		For
2.		The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm.		Management		For		For
3.		Non-binding advisory vote for the approval of the compensation of the named executive officers as disclosed in the 2023 proxy statement.		Management		For		For
4.		Non-binding advisory vote for the approval of the frequency with which future stockholder votes on the compensation of the named executive officers will be held.		Management		1 Year		For

 

ICON PLC

 

Security	G4705A100	Meeting Type	Annual
Ticker Symbol	ICLR	Meeting Date	26-Jul-2022
Record Date	06-Jun-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Director: Dr. Steve Cutler		Management		For		For
1.2		Election of Director: Dr. John Climax		Management		For		For
1.3		Election of Director: Mr. Ronan Murphy		Management		For		For
2.		To review the Company's affairs and consider the Accounts and Reports		Management		For		For
3.		To authorise the fixing of the Auditors' Remuneration		Management		For		For
4.		To authorise the Company to allot shares		Management		For		For
5.		To disapply the statutory pre-emption rights		Management		For		For
6.		To disapply the statutory pre-emption rights for funding capital investment or acquisitions		Management		For		For
7.		To authorise the Company to make market purchases of shares		Management		For		For
8.		To authorise the price range at which the Company can reissue shares that it holds as treasury shares		Management		For		For

 

 

IDEXX LABORATORIES, INC.

 

Security	45168D104	Meeting Type	Annual
Ticker Symbol	IDXX	Meeting Date	17-May-2023
Record Date	20-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director (Proposal One): Daniel M. Junius		Management		For		For
1b.		Election of Director (Proposal One): Lawrence D. Kingsley		Management		For		For
1c.		Election of Director (Proposal One): Sophie V. Vandebroek, PhD		Management		For		For
2.		Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year (Proposal Two).		Management		For		For
3.		Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation (Proposal Three).		Management		For		For
4.		Advisory Vote on the Frequency of Advisory Votes on Executive Compensation. To recommend, by nonbinding advisory vote, the frequency of future advisory votes on the Company's executive compensation (Proposal Four).		Management		1 Year		For

 

 

ILLUMINA, INC.

 

Security	452327109	Meeting Type	Contested-Annual
Ticker Symbol	ILMN	Meeting Date	25-May-2023
Record Date	03-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1A.		Illumina Nominee: Frances Arnold, Ph.D.		Management		For		For
1B.		Illumina Nominee: Francis A. deSouza		Management		Withheld		For
1C.		Illumina Nominee: Caroline D. Dorsa		Management		Withheld		For
1D.		Illumina Nominee: Robert S. Epstein, M.D.		Management		Withheld		For
1E.		Illumina Nominee: Scott Gottlieb, M.D.		Management		For		For
1F.		Illumina Nominee: Gary S. Guthart, Ph.D.		Management		Withheld		For
1G.		Illumina Nominee: Philip W. Schiller		Management		For		For
1H.		Illumina Nominee: Susan E. Siegel		Management		For		For
1I.		Illumina Nominee: John W. Thompson		Management		Withheld		For
1J.		Icahn Group Nominee OPPOSED by the Company: Vincent J. Intrieri		Management		For		For
1K.		Icahn Group Nominee OPPOSED by the Company: Jesse A. Lynn		Management		Withheld		For
1L.		Icahn Group Nominee OPPOSED by the Company: Andrew J. Teno		Management		Withheld		For
2.		To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For
3.		To approve, on an advisory basis, the compensation provided to our named executive officers as disclosed in the Proxy Statement.		Management		Against		Against
4.		To approve, on an advisory basis, the frequency of holding an advisory vote to approve compensation provided to our "named executive officers".		Management		1 Year		For
5.		To approve certain amendments to the Illumina, Inc. 2015 Stock and Incentive Plan		Management		For		For

 

 

INTELLIA THERAPEUTICS, INC.

 

Security	45826J105	Meeting Type	Annual
Ticker Symbol	NTLA	Meeting Date	14-Jun-2023
Record Date	17-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Muna Bhanji, R.Ph.				For		For
		2	John F. Crowley				For		For
		3	Jesse Goodman, MD, MPH				For		For
2.		Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2023.			Management		For		For
3.		Approve, on a non-binding advisory basis, the compensation of the named executive officers.			Management		For		For
4.		Approval of an amendment to our Second Amended and Restated Certificate of Incorporation to increase the number of authorizeds shares of common stock from 120,000,000 to 240,000,000.			Management		For		For

 

INTERCEPT PHARMACEUTICALS, INC.

 

Security	45845P108	Meeting Type	Annual
Ticker Symbol	ICPT	Meeting Date	24-May-2023
Record Date	31-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director to serve until the 2024 Annual Meeting: Paolo Fundarò		Management		For		For
1b.		Election of Director to serve until the 2024 Annual Meeting: Jerome Durso		Management		For		For
1c.		Election of Director to serve until the 2024 Annual Meeting: Srinivas Akkaraju, M.D., Ph.D.		Management		For		For
1d.		Election of Director to serve until the 2024 Annual Meeting: Luca Benatti, Ph.D.		Management		For		For
1e.		Election of Director to serve until the 2024 Annual Meeting: Daniel Bradbury		Management		For		For
1f.		Election of Director to serve until the 2024 Annual Meeting: Keith Gottesdiener, M.D.		Management		For		For
1g.		Election of Director to serve until the 2024 Annual Meeting: Nancy Miller-Rich		Management		For		For
1h.		Election of Director to serve until the 2024 Annual Meeting: Mark Pruzanski, M.D.		Management		For		For
1i.		Election of Director to serve until the 2024 Annual Meeting: Dagmar Rosa-Bjorkeson		Management		For		For
1j.		Election of Director to serve until the 2024 Annual Meeting: Gino Santini		Management		For		For
1k.		Election of Director to serve until the 2024 Annual Meeting: Glenn Sblendorio		Management		For		For
2.		FOR the approval of the Company's 2023 Equity Incentive Plan.		Management		For		For
3.		FOR the approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.		Management		For		For
4.		FOR the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.		Management		For		For

 

 

INTRA-CELLULAR THERAPIES, INC.

 

Security	46116X101	Meeting Type	Annual
Ticker Symbol	ITCI	Meeting Date	23-Jun-2023
Record Date	27-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Director: Eduardo Rene Salas		Management		For		For
2.		To ratify of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.		Management		For		For
3.		To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.		Management		For		For

 

INTUITIVE SURGICAL, INC.

 

Security	46120E602	Meeting Type	Annual
Ticker Symbol	ISRG	Meeting Date	27-Apr-2023
Record Date	28-Feb-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Craig H. Barratt, Ph.D.		Management		For		For
1b.		Election of Director: Joseph C. Beery		Management		For		For
1c.		Election of Director: Gary S. Guthart, Ph.D.		Management		For		For
1d.		Election of Director: Amal M. Johnson		Management		For		For
1e.		Election of Director: Don R. Kania, Ph.D.		Management		For		For
1f.		Election of Director: Amy L. Ladd, M.D.		Management		For		For
1g.		Election of Director: Keith R. Leonard, Jr.		Management		For		For
1h.		Election of Director: Alan J. Levy, Ph.D.		Management		For		For
1i.		Election of Director: Jami Dover Nachtsheim		Management		For		For
1j.		Election of Director: Monica P. Reed, M.D.		Management		For		For
1k.		Election of Director: Mark J. Rubash		Management		For		For
2.		To approve, by advisory vote, the compensation of the Company's Named Executive Officers		Management		For		For
3.		To approve, by advisory vote, the frequency of the advisory vote on the compensation of the Company's Named Executive Officers.		Management		1 Year		For
4.		The ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For
5.		The stockholder proposal regarding pay equity disclosure.		Shareholder		Against		For

 

 

IO LIGHT HOLDINGS, INC.

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	27-Sep-2022
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Approval of Subsidiary Transfer Documents		Management		For		For
2.		General Resolutions		Management		For		For

 

IO LIGHT HOLDINGS, INC.

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	30-Dec-2022
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Approval of Series B Financing		Management		For		For
2.		Approval of Amended and Restated Certification of Incorporation		Management		For		For
3.		Approval of Amended and Restated Stockholders Agreement		Management		For		For

 

IONIS PHARMACEUTICALS, INC.

 

Security	462222100	Meeting Type	Annual
Ticker Symbol	IONS	Meeting Date	01-Jun-2023
Record Date	03-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Spencer R. Berthelsen				For		For
		2	Joan E. Herman				For		For
		3	B. Lynne Parshall				For		For
		4	Joseph H. Wender				For		For
2.		To approve, by non-binding vote, executive compensation.			Management		For		For
3.		To approve, by non-binding vote, the frequency of future advisory votes on executive compensation.			Management		1 Year		For
4.		To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 5,500,000 shares to an aggregate of 35,200,000 shares.			Management		For		For
5.		To ratify increasing the vesting of future initial stock option and restricted stock unit awards to new non-employee Directors from one year to three years.			Management		For		For
6.		To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2023 fiscal year.			Management		For		For

 

 

IQVIA HOLDINGS INC.

 

Security	46266C105	Meeting Type	Annual
Ticker Symbol	IQV	Meeting Date	18-Apr-2023
Record Date	17-Feb-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Carol J. Burt		Management		For		For
1b.		Election of Director: Colleen A. Goggins		Management		For		For
1c.		Election of Director: Sheila A. Stamps		Management		For		For
2.		Approve an advisory (non-binding) resolution to approve IQVIA's executive compensation (say-on-pay).		Management		For		For
3.		Approve a Company proposal to amend IQVIA's Certificate of Incorporation to adopt a stockholders' right to request a special stockholders' meeting.		Management		For		For
4.		If properly presented, a stockholder proposal concerning special stockholder meetings.		Shareholder		For		Against
5.		If properly presented, a stockholder proposal for separate Chairman and Chief Executive Officer roles.		Shareholder		For		Against
6.		Ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA's independent registered public accounting firm for 2023.		Management		For		For

 

JAZZ PHARMACEUTICALS PLC

 

Security	G50871105	Meeting Type	Annual
Ticker Symbol	JAZZ	Meeting Date	28-Jul-2022
Record Date	01-Jun-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director to hold office until the 2025 Annual General Meeting: Jennifer E. Cook		Management		For		For
1b.		Election of Director to hold office until the 2025 Annual General Meeting: Patrick G. Enright		Management		For		For
1c.		Election of Director to hold office until the 2025 Annual General Meeting: Seamus Mulligan		Management		For		For
1d.		Election of Director to hold office until the 2025 Annual General Meeting: Norbert G. Riedel, Ph.D.		Management		For		For
2.		To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2022 and to authorize, in a binding vote, the Board of Directors, acting through the audit committee, to determine KPMG's remuneration.		Management		For		For
3.		To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement.		Management		For		For
4.		To grant the Board of Directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply.		Management		For		For
5.		To approve any motion to adjourn the Annual General Meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting to approve Proposal 4.		Management		For		For

 

 

JOHNSON & JOHNSON

 

Security	478160104	Meeting Type	Annual
Ticker Symbol	JNJ	Meeting Date	27-Apr-2023
Record Date	28-Feb-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Darius Adamczyk		Management		For		For
1b.		Election of Director: Mary C. Beckerle		Management		For		For
1c.		Election of Director: D. Scott Davis		Management		For		For
1d.		Election of Director: Jennifer A. Doudna		Management		For		For
1e.		Election of Director: Joaquin Duato		Management		For		For
1f.		Election of Director: Marillyn A. Hewson		Management		For		For
1g.		Election of Director: Paula A. Johnson		Management		For		For
1h.		Election of Director: Hubert Joly		Management		For		For
1I.		Election of Director: Mark B. McClellan		Management		For		For
1j.		Election of Director: Anne M. Mulcahy		Management		For		For
1k.		Election of Director: Mark A. Weinberger		Management		For		For
1l.		Election of Director: Nadja Y. West		Management		For		For
2.		Advisory Vote to Approve Named Executive Officer Compensation		Management		For		For
3.		Advisory Vote on the Frequency of Voting to Approve Named Executive Officer Compensation		Management		1 Year		For
4.		Ratification of Appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting Firm		Management		For		For
5.		Proposal Withdrawn (Federal Securities Laws Mandatory Arbitration Bylaw)		Shareholder		Abstain
6.		Vaccine Pricing Report		Shareholder		Against		For
7.		Executive Compensation Adjustment Policy		Shareholder		Against		For
8.		Impact of Extended Patent Exclusivities on Product Access		Shareholder		Against		For

 

 

KARUNA THERAPEUTICS, INC.

 

Security	48576A100	Meeting Type	Annual
Ticker Symbol	KRTX	Meeting Date	20-Jun-2023
Record Date	24-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Bill Meury		Management		For		For
1b.		Election of Director: Laurie Olson		Management		For		For
1c.		Election of Director: David Wheadon, M.D.		Management		For		For
2.		To approve, on an advisory, non-binding basis, the compensation paid to our named executive officers.		Management		For		For
3.		To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For

 

KURA ONCOLOGY, INC.

 

Security	50127T109	Meeting Type	Annual
Ticker Symbol	KURA	Meeting Date	31-May-2023
Record Date	03-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Class III Director for three-year term: Diane Parks		Management		For		For
1.2		Election of Class III Director for three-year term: Mary T. Szela		Management		For		For
2.		Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023.		Management		For		For
3.		Approval, on an advisory basis, of the compensation of our named executive officers during the year ended December 31, 2022.		Management		For		For
4.		Approval of an amendment to our Amended and Restated 2014 Equity Incentive Plan.		Management		For		For

 

 

LABORATORY CORP. OF AMERICA HOLDINGS

 

Security	50540R409	Meeting Type	Annual
Ticker Symbol	LH	Meeting Date	11-May-2023
Record Date	16-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Kerrii B. Anderson		Management		For		For
1b.		Election of Director: Jean-Luc Bélingard		Management		For		For
1c.		Election of Director: Jeffrey A. Davis		Management		For		For
1d.		Election of Director: D. Gary Gilliland, M.D., Ph.D.		Management		For		For
1e.		Election of Director: Kirsten M. Kliphouse		Management		For		For
1f.		Election of Director: Garheng Kong, M.D., Ph.D.		Management		For		For
1g.		Election of Director: Peter M. Neupert		Management		For		For
1h.		Election of Director: Richelle P. Parham		Management		For		For
1i.		Election of Director: Adam H. Schechter		Management		For		For
1j.		Election of Director: Kathryn E. Wengel		Management		For		For
1k.		Election of Director: R. Sanders Williams, M.D.		Management		For		For
2.		To approve, by non-binding vote, executive compensation.		Management		For		For
3.		To recommend by non-binding vote, the frequency of future non-binding votes on executive compensation.		Management		1 Year		For
4.		Ratification of the appointment of Deloitte and Touche LLP as Laboratory Corporation of America Holdings' independent registered public accounting firm for the year ending December 31, 2023.		Management		For		For
5.		Shareholder proposal relating to a policy regarding separation of the roles of Board Chairman and Chief Executive Officer.		Shareholder		For		Against
6.		Shareholder proposal regarding a Board report on transport of nonhuman primates within the U.S.		Shareholder		Against		For
7.		Shareholder proposal regarding a Board report on known risks of fulfilling information requests and mitigation strategies.		Shareholder		Against		For

 

LANTHEUS HOLDINGS, INC.

 

Security	516544103	Meeting Type	Annual
Ticker Symbol	LNTH	Meeting Date	27-Apr-2023
Record Date	06-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Class II Director: Ms. Minnie Baylor-Henry		Management		For		For
1.2		Election of Class II Director: Mr. Heinz Mäusli		Management		For		For
1.3		Election of Class II Director: Ms. Julie McHugh		Management		For		For
2.		The approval, on an advisory basis, of the compensation paid to our named executive officers.		Management		For		For
3.		The approval of the Lantheus Holdings, Inc. 2023 Employee Stock Purchase Plan.		Management		For		For
4.		The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For

 

 

MADRIGAL PHARMACEUTICALS INC.

 

Security	558868105	Meeting Type	Annual
Ticker Symbol	MDGL	Meeting Date	15-Jun-2023
Record Date	27-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Re-election of Class I Director: Paul A. Friedman, M.D.		Management		For		For
1.2		Re-election of Class I Director: Kenneth M. Bate		Management		For		For
1.3		Re-election of Class I Director: James M. Daly		Management		For		For
2.		To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For
3.		Advisory vote to approve executive compensation.		Management		For		For
4.		Amendment of Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.		Management		For		For

 

MARINUS PHARMACEUTICALS, INC.

 

Security	56854Q200	Meeting Type	Annual
Ticker Symbol	MRNS	Meeting Date	24-May-2023
Record Date	27-Mar-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Tim M. Mayleben				For		For
		2	Saraswathy V Nochur PhD				For		For
		3	Christine Silverstein				For		For
2.		Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.			Management		For		For
3.		Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.			Management		For		For

 

 

MCKESSON CORPORATION

 

Security	58155Q103	Meeting Type	Annual
Ticker Symbol	MCK	Meeting Date	22-Jul-2022
Record Date	27-May-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director for a one-year term: Richard H. Carmona, M.D.		Management		For		For
1b.		Election of Director for a one-year term: Dominic J. Caruso		Management		For		For
1c.		Election of Director for a one-year term: W. Roy Dunbar		Management		For		For
1d.		Election of Director for a one-year term: James H. Hinton		Management		For		For
1e.		Election of Director for a one-year term: Donald R. Knauss		Management		For		For
1f.		Election of Director for a one-year term: Bradley E. Lerman		Management		For		For
1g.		Election of Director for a one-year term: Linda P. Mantia		Management		For		For
1h.		Election of Director for a one-year term: Maria Martinez		Management		For		For
1i.		Election of Director for a one-year term: Susan R. Salka		Management		For		For
1j.		Election of Director for a one-year term: Brian S. Tyler		Management		For		For
1k.		Election of Director for a one-year term: Kathleen Wilson-Thompson		Management		For		For
2.		Ratification of Appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2023.		Management		For		For
3.		Advisory vote on executive compensation.		Management		For		For
4.		Approval of our 2022 Stock Plan.		Management		For		For
5.		Approval of Amendment to our 2000 Employee Stock Purchase Plan.		Management		For		For
6.		Shareholder Proposal on Special Shareholder Meeting Improvement.		Shareholder		Against		For
7.		Shareholder Proposal on Transparency in Rule 10b5-1 Trading Policy.		Shareholder		Against		For

 

MEDPACE HOLDINGS, INC.

 

Security	58506Q109	Meeting Type	Annual
Ticker Symbol	MEDP	Meeting Date	19-May-2023
Record Date	23-Mar-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Brian T. Carley				For		For
		2	F. H. Gwadry-Sridhar				For		For
		3	Robert O. Kraft				For		For
2.		To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.			Management		For		For
3.		To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2023 Annual Meeting.			Management		For		For

 

 

MEDTRONIC PLC

 

Security	G5960L103	Meeting Type	Annual
Ticker Symbol	MDT	Meeting Date	08-Dec-2022
Record Date	11-Oct-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director to hold office until the 2023 Annual General Meeting: Richard H. Anderson		Management		For		For
1b.		Election of Director to hold office until the 2023 Annual General Meeting: Craig Arnold		Management		For		For
1c.		Election of Director to hold office until the 2023 Annual General Meeting: Scott C. Donnelly		Management		For		For
1d.		Election of Director to hold office until the 2023 Annual General Meeting: Lidia L. Fonseca		Management		For		For
1e.		Election of Director to hold office until the 2023 Annual General Meeting: Andrea J. Goldsmith, Ph.D.		Management		For		For
1f.		Election of Director to hold office until the 2023 Annual General Meeting: Randall J. Hogan, III		Management		For		For
1g.		Election of Director to hold office until the 2023 Annual General Meeting: Kevin E. Lofton		Management		For		For
1h.		Election of Director to hold office until the 2023 Annual General Meeting: Geoffrey S. Martha		Management		For		For
1i.		Election of Director to hold office until the 2023 Annual General Meeting: Elizabeth G. Nabel, M.D.		Management		For		For
1j.		Election of Director to hold office until the 2023 Annual General Meeting: Denise M. O'Leary		Management		For		For
1k.		Election of Director to hold office until the 2023 Annual General Meeting: Kendall J. Powell		Management		For		For
2.		Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for fiscal year 2023 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor's remuneration.		Management		For		For
3.		Approving, on an advisory basis, the Company's executive compensation.		Management		For		For
4.		Renewing the Board of Directors' authority to issue shares under Irish law.		Management		For		For
5.		Renewing the Board of Directors' authority to opt out of pre-emption rights under Irish law.		Management		For		For
6.		Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares.		Management		For		For

 

 

MERCK & CO., INC.

 

Security	58933Y105	Meeting Type	Annual
Ticker Symbol	MRK	Meeting Date	23-May-2023
Record Date	24-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Douglas M. Baker, Jr.		Management		For		For
1b.		Election of Director: Mary Ellen Coe		Management		For		For
1c.		Election of Director: Pamela J. Craig		Management		For		For
1d.		Election of Director: Robert M. Davis		Management		For		For
1e.		Election of Director: Thomas H. Glocer		Management		For		For
1f.		Election of Director: Risa J. Lavizzo-Mourey, M.D.		Management		For		For
1g.		Election of Director: Stephen L. Mayo, Ph.D.		Management		For		For
1h.		Election of Director: Paul B. Rothman, M.D.		Management		For		For
1i.		Election of Director: Patricia F. Russo		Management		For		For
1j.		Election of Director: Christine E. Seidman, M.D.		Management		For		For
1k.		Election of Director: Inge G. Thulin		Management		For		For
1l.		Election of Director: Kathy J. Warden		Management		For		For
1m.		Election of Director: Peter C. Wendell		Management		For		For
2.		Non-binding advisory vote to approve the compensation of our named executive officers.		Management		For		For
3.		Non-binding advisory vote to approve the frequency of future votes to approve the compensation of our named executive officers.		Management		1 Year		For
4.		Ratification of the appointment of the Company's independent registered public accounting firm for 2023.		Management		For		For
5.		Shareholder proposal regarding business operations in China.		Shareholder		Against		For
6.		Shareholder proposal regarding access to COVID-19 products.		Shareholder		Against		For
7.		Shareholder proposal regarding indirect political spending.		Shareholder		Against		For
8.		Shareholder proposal regarding patents and access.		Shareholder		Against		For
9.		Shareholder proposal regarding a congruency report of partnerships with globalist organizations.		Shareholder		Against		For
10.		Shareholder proposal regarding an independent board chairman.		Shareholder		For		Against

 

MEREO BIOPHARMA GROUP PLC

 

Security	589492107	Meeting Type	Special
Ticker Symbol	MREO	Meeting Date	18-Nov-2022
Record Date	14-Oct-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		THAT Dr. Peter Fellner, Dr. Anders Ekblom, Dr. Deepika Pakianathan, Dr. Brian Schwartz and Mr. Michael Wyzga be removed from office as directors of the Company with immediate effect.		Management		Against		For
2.		THAT, conditional upon the passing of resolution 1 above, Dr. Annalisa Jenkins be appointed as director of the Company with immediate effect.		Management		Against		For
3.		THAT, conditional upon the passing of resolution 1 above, Dr. Daniel Shames be appointed as director of the Company with immediate effect.		Management		Against		For
4.		THAT, conditional upon the passing of resolution 1 above, Mr. Marc Yoskowitz be appointed as director of the Company with immediate effect.		Management		Against		For
5.		THAT, conditional upon the passing of resolution 1 above, Mr. Justin Roberts be appointed as director of the Company with immediate effect.		Management		Against		For
6.		THAT, conditional upon the passing of resolution 1 above, Mr. David Rosen be appointed as director of the Company with immediate effect.		Management		Against		For

 

 

MEREO BIOPHARMA GROUP PLC

 

Security	589492107	Meeting Type	Annual
Ticker Symbol	MREO	Meeting Date	22-May-2023
Record Date	10-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		That the annual report and accounts for the financial year ended 31 December 2022, together with the directors' report and independent auditor's report thereon, be received and adopted.		Management		For		For
2.		That BDO LLP be re-appointed as auditors to hold office from the conclusion of the AGM until the conclusion of the next annual general meeting at which the Company's annual report and accounts are presented.		Management		For		For
3.		That the Directors be authorised to determine BDO LLP's remuneration.		Management		For		For
4.		That the directors' remuneration report (excluding the directors' remuneration policy), as set out in the Company's annual report and accounts for the financial year ended 31 December 2022, be approved.		Management		For		For
5.		That the directors' remuneration policy as set out in the Company's annual report and accounts for the financial year ended 31 December 2022, which takes effect from the end of this AGM, be approved.		Management		For		For
6.		That Dr. Annalisa Jenkins be re-appointed as a director of the Company.		Management		For		For
7.		That Justin Roberts be re-appointed as a director of the Company.		Management		For		For
8.		That Dr. Daniel Shames be re-appointed as a director of the Company.		Management		For		For
9.		That Marc Yoskowitz be re-appointed as a director of the Company.		Management		For		For
10.		That the Directors be generally and unconditionally authorised in accordance with section 551 of the Companies Act 2006 (the "Act") to exercise all the powers of the Company to allot shares in the Company or to grant rights to subscribe for, or to convert securities into, shares in the Company up to a maximum aggregate nominal amount of £2,494,456.76, such authority to expire on 30 June 2026, save that the Company may, before such expiry, make offers or agreements which would, or might, require ...(due to space limits, see proxy material for full proposal).		Management		For		For
11.		That, subject to Resolution 10 being passed, the Directors be generally empowered pursuant to section 570 and section 573 of the Act to allot equity securities for cash pursuant to the authority given by Resolution 10 and to sell equity securities held as treasury shares for cash pursuant to section 727 of the Act, in each case as if section 561(1) of the Act did not apply to any such allotment or sale, provided that this power shall be limited to the allotment or sale of equity securities up to an ...(due to space limits, see proxy material for full proposal).		Management		For		For

 

 

MIRATI THERAPEUTICS, INC.

 

Security	60468T105	Meeting Type	Annual
Ticker Symbol	MRTX	Meeting Date	11-May-2023
Record Date	15-Mar-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Charles M. Baum				For		For
		2	Bruce L.A. Carter				For		For
		3	Julie M. Cherrington				For		For
		4	Aaron I. Davis				For		For
		5	Faheem Hasnain				For		For
		6	Craig Johnson				For		For
		7	Maya Martinez-Davis				For		For
		8	David Meek				For		For
		9	Shalini Sharp				For		For
2.		To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in the Proxy Statement.			Management		For		For
3.		To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023.			Management		For		For
4.		To approve the amendment to our 2013 Employee Stock Purchase Plan, to increase the aggregate number of shares of our common stock reserved for issuance under such plan by 750,000 shares.			Management		For		For

 

MODERNA, INC.

 

Security	60770K107	Meeting Type	Annual
Ticker Symbol	MRNA	Meeting Date	03-May-2023
Record Date	08-Mar-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Stephen Berenson				For		For
		2	Sandra Horning, M.D.				For		For
		3	Paul Sagan				For		For
2.		To approve, on a non-binding, advisory basis, the compensation of our named executive officers.			Management		For		For
3.		To ratify the appointment of Ernst & Young LLP as our registered independent public accounting firm for the year ending December 31, 2023.			Management		For		For
4.		To vote on a shareholder proposal requesting a report on transferring intellectual property.			Shareholder		Against		For

 

 

MOLINA HEALTHCARE, INC.

 

Security	60855R100	Meeting Type	Annual
Ticker Symbol	MOH	Meeting Date	03-May-2023
Record Date	08-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director to hold office until the 2024 Annual Meeting: Barbara L. Brasier		Management		For		For
1b.		Election of Director to hold office until the 2024 Annual Meeting: Daniel Cooperman		Management		For		For
1c.		Election of Director to hold office until the 2024 Annual Meeting: Stephen H. Lockhart		Management		For		For
1d.		Election of Director to hold office until the 2024 Annual Meeting: Steven J. Orlando		Management		For		For
1e.		Election of Director to hold office until the 2024 Annual Meeting: Ronna E. Romney		Management		For		For
1f.		Election of Director to hold office until the 2024 Annual Meeting: Richard M. Schapiro		Management		For		For
1g.		Election of Director to hold office until the 2024 Annual Meeting: Dale B. Wolf		Management		For		For
1h.		Election of Director to hold office until the 2024 Annual Meeting: Richard C. Zoretic		Management		For		For
1i.		Election of Director to hold office until the 2024 Annual Meeting: Joseph M. Zubretsky		Management		For		For
2.		To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers.		Management		For		For
3.		To conduct an advisory vote on the frequency of a stockholder vote on the compensation of our named executive officers.		Management		1 Year		For
4.		To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2023.		Management		For		For

 

 

NEUROCRINE BIOSCIENCES, INC.

 

Security	64125C109	Meeting Type	Annual
Ticker Symbol	NBIX	Meeting Date	17-May-2023
Record Date	20-Mar-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Kevin C. Gorman, Ph.D.				For		For
		2	Gary A. Lyons				For		For
		3	Johanna Mercier				For		For
2.		Advisory vote to approve the compensation paid to the Company's named executive officers.			Management		For		For
3.		Advisory vote on the frequency of advisory votes to approve the compensation paid to the Company's named executive officers.			Management		1 Year		For
4.		To approve an amendment to the Company's 2020 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 6,600,000 shares.			Management		Against		Against
5.		To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.			Management		For		For

 

NEXGEL, INC.

 

Security	65344E107	Meeting Type	Annual
Ticker Symbol	NXGL	Meeting Date	30-Aug-2022
Record Date	06-Jul-2022

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Adam Levy				For		For
		2	Steven Glassman				For		For
		3	Yaakov Spinrad				For		For
		4	David Stefansky				For		For
		5	Nachum Stein				For		For
		6	Miranda J. Toledano				For		For
		7	Dr. J.B. Zeldis MD, PhD				For		For
2.		Proposal to approve an amendment to our Restated Certificate of Incorporation (the "Charter"), in substantially the form attached to the proxy statement as Annex A, reduce the total number of authorized shares of our common stock, par value $0.001 per share, each from 750,000,000 to 25,000,000.			Management		For		For
3.		Advisory vote on the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this notice.			Management		For		For
4.		Advisory vote on the frequency of future advisory votes on the compensation of the Company's named executive officers.			Management		1 Year		Against
5.		Ratification of the appointment of Turner, Stone & Company, L.L.P. as the Company's independent registered public accounting firm for the 2022 fiscal year.			Management		For		For

 

 

NEXGEL, INC.

 

Security	65344E107	Meeting Type	Annual
Ticker Symbol	NXGL	Meeting Date	06-Jun-2023
Record Date	11-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Adam Levy				For		For
		2	Steven Glassman				For		For
		3	Scott R. Henry				For		For
		4	David Stefansky				For		For
		5	Nachum Stein				For		For
		6	Miranda J. Toledano				For		For
		7	Dr. J.B. Zeldis MD, PhD				For		For
2.		Proposal to approve the Third Amendment to the NexGel, Inc. 2019 Long-Term Incentive Plan to increase the total number of shares of common stock authorized for issuance under such plan by 300,000, to a total of 871,429 shares.			Management		For		For
3.		Ratification of the appointment of Turner, Stone & Company, L.L.P. as the Company's independent registered public accounting firm for the 2023 fiscal year.			Management		For		For

 

NOVAVAX, INC.

 

Security	670002401	Meeting Type	Annual
Ticker Symbol	NVAX	Meeting Date	11-Jul-2023
Record Date	18-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Class I Director to serve for a three-year term expiring at the 2026 Annual Meeting: John C. Jacobs		Management		For		For
1b.		Election of Class I Director to serve for a three-year term expiring at the 2026 Annual Meeting: Gregg H. Alton, J.D.		Management		For		For
1c.		Election of Class I Director to serve for a three-year term expiring at the 2026 Annual Meeting: Richard J. Rodgers		Management		For		For
2.		The approval, on an advisory basis, of the compensation paid to our Named Executive Officers.		Management		For		For
3.		The approval, on an advisory basis, of holding future executive compensation advisory votes every three years, every two years, or every year.		Management		1 Year		For
4.		Amendment to the Second Amended and Restated Certificate of Incorporation of Novavax, Inc., as amended, to reflect Delaware law provisions allowing officer exculpation.		Management		For		For
5.		Amendment and restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended to increase the number of shares of common stock available for issuance thereunder by 6,170,000 shares.		Management		Against		Against
6.		Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For

 

 

OCULIS HOLDING AG

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	8-Jul-2022
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1		Change of Designation of the Existing Series C Preferred Shares and Revision of the Articles of Association		Management		For		For
2.		Ordinary Share Capital Increase		Management		For		For
3.		Conditional Share Capital Increase		Management		For		For
4.		Election of Member to the Board of Directors		Management		For		For

 

PARTHENON THERAPEUTICS, INC

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	21-Feb-2023
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1		Pursuant to Section 1.2(e) of the Voting Agreement, Laurent Audoly be, and he hereby is, removed as the CEO Director and as a member of the Board, in each case with immediate effect		Management		For		For
2.		Following the removal of Dr. Audoly as the CEO Director pursuant to the foregoing, the CEO Director seat shall remain vacant in accordance with Section 1.2(e) of the Voting Agreement until a new Chief Executive Officer of the Company is duly qualified and appointed		Management		For		For
3.		The proper officers of the Company be, and each of them hereby is, authorized and directed, in the name of and on behalf of the Company, to prepare or cause to be prepared and to execute, deliver, verify, acknowledge, file or record any documents, instruments, certificates, statements, papers, or any amendments thereto, as in their sole judgment may be necessary, appropriate or advisable in order to effect the foregoing resolutions, and to take such further steps and do all such further acts or things as in their sole judgment may be necessary, appropriate or advisable to carry out the foregoing resolutions		Management		For		For
4.		The authority and power given hereunder be deemed retroactive and any and all actions previously taken by any officer or director of the Company in connection with these resolutions are hereby ratified and approved		Management		For		For

 

 

PERRIGO COMPANY PLC

 

Security	G97822103	Meeting Type	Annual
Ticker Symbol	PRGO	Meeting Date	04-May-2023
Record Date	06-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1A.		Election of Director to hold office until the 2024 Annual General Meeting: Bradley A. Alford		Management		For		For
1B.		Election of Director to hold office until the 2024 Annual General Meeting: Orlando D. Ashford		Management		For		For
1C.		Election of Director to hold office until the 2024 Annual General Meeting: Katherine C. Doyle		Management		For		For
1D.		Election of Director to hold office until the 2024 Annual General Meeting: Adriana Karaboutis		Management		For		For
1E.		Election of Director to hold office until the 2024 Annual General Meeting: Murray S. Kessler		Management		For		For
1F.		Election of Director to hold office until the 2024 Annual General Meeting: Jeffrey B. Kindler		Management		For		For
1G.		Election of Director to hold office until the 2024 Annual General Meeting: Erica L. Mann		Management		For		For
1H.		Election of Director to hold office until the 2024 Annual General Meeting: Albert A. Manzone		Management		For		For
1I.		Election of Director to hold office until the 2024 Annual General Meeting: Donal O'Connor		Management		For		For
1J.		Election of Director to hold office until the 2024 Annual General Meeting: Geoffrey M. Parker		Management		For		For
2.		Ratify, in a non-binding advisory vote, the appointment of Ernst & Young LLP as the Company's independent auditor, and authorize, in a binding vote, the Board of Directors, acting through the Audit Committee, to fix the remuneration of the auditor		Management		For		For
3.		Advisory vote on executive compensation		Management		For		For
4.		Advisory vote on the frequency of future advisory votes on executive compensation		Management		1 Year		For
5.		Renew the Board's authority to issue shares under Irish law		Management		For		For
6.		Renew the Board's authority to opt-out of statutory pre-emption rights under Irish law		Management		For		For
7.		Approve the creation of distributable reserves by reducing some or all of the Company's share premium		Management		For		For

 

 

PFIZER INC.

 

Security	717081103	Meeting Type	Annual
Ticker Symbol	PFE	Meeting Date	27-Apr-2023
Record Date	01-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Ronald E. Blaylock		Management		For		For
1b.		Election of Director: Albert Bourla		Management		For		For
1c.		Election of Director: Susan Desmond-Hellmann		Management		For		For
1d.		Election of Director: Joseph J. Echevarria		Management		For		For
1e.		Election of Director: Scott Gottlieb		Management		For		For
1f.		Election of Director: Helen H. Hobbs		Management		For		For
1g.		Election of Director: Susan Hockfield		Management		For		For
1h.		Election of Director: Dan R. Littman		Management		For		For
1i.		Election of Director: Shantanu Narayen		Management		For		For
1j.		Election of Director: Suzanne Nora Johnson		Management		For		For
1k.		Election of Director: James Quincey		Management		For		For
1l.		Election of Director: James C. Smith		Management		For		For
2.		Ratify the selection of KPMG LLP as independent registered public accounting firm for 2023		Management		For		For
3.		2023 advisory approval of executive compensation		Management		For		For
4.		Advisory vote on frequency of future advisory votes to approve executive compensation		Management		1 Year		For
5.		Shareholder proposal regarding ratification of termination pay		Shareholder		Against		For
6.		Shareholder proposal regarding independent board chairman policy		Shareholder		For		Against
7.		Shareholder proposal regarding transfer of intellectual property to potential COVID-19 manufacturers feasibility report		Shareholder		Against		For
8.		Shareholder proposal regarding impact of extended patent exclusivities on product access report		Shareholder		Against		For
9.		Shareholder proposal regarding political contributions congruency report		Shareholder		Against		For

 

 

PRAXIS PRECISION MEDICINES, INC.

 

Security	74006W108	Meeting Type	Annual
Ticker Symbol	PRAX	Meeting Date	12-Jun-2023
Record Date	17-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Class III Director to serve until the 2026 Annual Meeting of Stockholders: Gregory Norden		Management		For		For
1b.		Election of Class III Director to serve until the 2026 Annual Meeting of Stockholders: Marcio Souza		Management		For		For
1c.		Election of Class III Director to serve until the 2026 Annual Meeting of Stockholders: William Young		Management		For		For
2.		To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For
3.		To approve on a non-binding, advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2023 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.		Management		For		For

 

PRECISION BIOSCIENCES, INC.

 

Security	74019P108	Meeting Type	Annual
Ticker Symbol	DTIL	Meeting Date	04-May-2023
Record Date	09-Mar-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Michael Amoroso				For		For
		2	Geno Germano				For		For
2.		Ratification of the appointment of Deloitte & Touche LLP as Precision's independent registered public accounting firm for 2023.			Management		For		For

 

 

PRIOTHERA LIMITED

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	5-Dec-2022
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Notice of Appointment of Authorized Person		Management		For		For

 

PROMETHEUS BIOSCIENCES, INC.

 

Security	74349U108	Meeting Type	Special
Ticker Symbol	RXDX	Meeting Date	15-Jun-2023
Record Date	15-May-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated as of April 15, 2023, by and among Merck & Co., Inc., a New Jersey corporation ("Merck"), Splash Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Merck ("Merger Sub"), and Prometheus Biosciences, Inc., a Delaware corporation ("Prometheus"), pursuant to which Merger Sub will be merged with and into Prometheus, with Prometheus surviving as a wholly owned subsidiary of Merck (the "Merger").		Management		For		For
2.		To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to Prometheus' named executive officers that is based on or otherwise relates to the Merger.		Management		For		For
3.		To approve the adjournment of the special meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes in person or by proxy to approve the proposal to adopt the Merger Agreement at the time of the special meeting.		Management		For		For

 

PYXIS ONCOLOGY, INC.

 

Security	747324101	Meeting Type	Annual
Ticker Symbol	PYXS	Meeting Date	13-Jun-2023
Record Date	20-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Director: Rachel Humphrey, M.D.		Management		For		For
1.2		Election of Director: Freda Lewis-Hall, M.D.		Management		For		For
1.3		Election of Director: Thomas Civik		Management		For		For
2.		Ratification of the Appointment of Ernst & Young LLP as our Independent Registered Public Accounting Firm for the Fiscal Year ending December 31, 2023		Management		For		For

 

 

QUELL THERAPEUTICS

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	2-Jun-2023
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Approval of the Limited Equity Incentive Plan		Management		For		For
2.		Approval of the new articles of association of the Company (the "New Articles") in substitution for, and to the entire exclusion of, the current articles of association of the Company		Management		For		For

 

RALLYBIO CORPORATION

 

Security	75120L100	Meeting Type	Annual
Ticker Symbol	RLYB	Meeting Date	17-May-2023
Record Date	20-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Class II Director: Helen M. Boudreau		Management		For		For
1.2		Election of Class II Director: Lucian Iancovici		Management		For		For
1.3		Election of Class II Director: Christine A. Nash		Management		For		For
2.		Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm.		Management		For		For

 

REATA PHARMACEUTICALS, INC.

 

Security	75615P103	Meeting Type	Annual
Ticker Symbol	RETA	Meeting Date	07-Jun-2023
Record Date	12-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Class II Director to serve until the 2026 Annual Meeting: Martin W. Edwards, M.D.		Management		For		For
1.2		Election of Class II Director to serve until the 2026 Annual Meeting: R. Kent McGaughy, Jr.		Management		For		For
1.3		Election of Class II Director to serve until the 2026 Annual Meeting: Christy J. Oliger		Management		For		For
2.		An advisory (non-binding) vote on a resolution to approve the compensation of our named executive officers.		Management		For		For
3.		The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For

 

 

RECODE THERAPEUTICS

 

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	6-Jan-2023
Record Date	N/A

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Amendment No. 2 to Series B Preferred Stock Purchase Agreement		Management		For		For

 

REGENERON PHARMACEUTICALS, INC.

 

Security	75886F107	Meeting Type	Annual
Ticker Symbol	REGN	Meeting Date	09-Jun-2023
Record Date	11-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Joseph L. Goldstein, M.D.		Management		For		For
1b.		Election of Director: Christine A. Poon		Management		For		For
1c.		Election of Director: Craig B. Thompson, M.D.		Management		For		For
1d.		Election of Director: Huda Y. Zoghbi, M.D.		Management		For		For
2.		Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For
3.		Proposal to approve, on an advisory basis, executive compensation.		Management		For		For
4.		Proposal to approve, on an advisory basis, the frequency of future advisory votes on executive compensation.		Management		1 Year		For
5.		Non-binding shareholder proposal, if properly presented, requesting report on a process by which access to medicine is considered in matters related to protecting intellectual property.		Shareholder		Against		For

 

 

SAREPTA THERAPEUTICS, INC.

 

Security	803607100	Meeting Type	Annual
Ticker Symbol	SRPT	Meeting Date	08-Jun-2023
Record Date	14-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Class II Director to hold office until the 2025 Annual Meeting: Richard J. Barry		Management		For		For
1.2		Election of Class II Director to hold office until the 2025 Annual Meeting: M. Kathleen Behrens, Ph.D.		Management		For		For
1.3		Election of Class II Director to hold office until the 2025 Annual Meeting: Stephen L. Mayo, Ph. D.		Management		For		For
1.4		Election of Class II Director to hold office until the 2025 Annual Meeting: Claude Nicaise, M.D.		Management		For		For
2.		Advisory vote to approve, on a non-binding basis, named executive officer compensation		Management		For		For
3.		Approve an amendment to the Company's 2018 Equity Incentive Plan (the "2018 Plan") to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 2,500,000 shares to 13,187,596 shares		Management		For		For
4.		Approve an amendment to the Amended and Restated 2013 Employee Stock Purchase Plan (as amended and restated on June 27, 2016 and amended on June 6, 2019) (the "2016 ESPP") to increase the number of shares of our common stock authorized for issuance under the 2016 ESPP by 300,000 shares to 1,400,000 shares		Management		For		For
5.		Advisory vote on whether an advisory vote on executive compensation should be held every one, two or three years		Management		1 Year		For
6.		Ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2023		Management		For		For

 

SCHOLAR ROCK HOLDING CORPORATION

 

Security	80706P103	Meeting Type	Annual
Ticker Symbol	SRRK	Meeting Date	21-Jun-2023
Record Date	24-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	David Hallal				For		For
		2	Kristina Burow				For		For
		3	Michael Gilman Ph.D				For		For
2.		To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.			Management		For		For

 

 

SEAGEN INC.

 

Security	81181C104	Meeting Type	Special
Ticker Symbol	SGEN	Meeting Date	30-May-2023
Record Date	17-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		To consider and vote on the proposal to adopt the Agreement and Plan of Merger (as it may be amended or supplemented from time to time, the "merger agreement"), dated March 12, 2023, by and among Seagen Inc. ("Seagen"), Pfizer Inc. ("Pfizer") and Aris Merger Sub, Inc., a wholly-owned subsidiary of Pfizer ("Merger Sub"), and pursuant to which Merger Sub will be merged with and into Seagen, with Seagen surviving the merger as a wholly-owned subsidiary of Pfizer (the "merger" and such proposal the "merger agreement proposal").		Management		For		For
2.		To consider and vote on the proposal to approve, on a non-binding, advisory basis, certain compensation arrangements for Seagen's named executive officers in connection with the merger (the "compensation proposal").		Management		For		For

 

SEAGEN INC.

 

Security	81181C104	Meeting Type	Annual
Ticker Symbol	SGEN	Meeting Date	31-May-2023
Record Date	03-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Class I Director: David W. Gryska		Management		For		For
1b.		Election of Class I Director: John A. Orwin		Management		For		For
1c.		Election of Class I Director: Alpna H. Seth, Ph.D.		Management		For		For
2.		Approve, on an advisory basis, the compensation of Seagen's named executive officers as disclosed in the accompanying proxy statement.		Management		For		For
3.		Indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of Seagen's named executive officers.		Management		1 Year		For
4.		Approve the amendment and restatement of the Seagen Inc. Amended and Restated 2007 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance thereunder by 5,190,000 shares.		Management		For		For
5.		Ratify the appointment of PricewaterhouseCoopers LLP as Seagen's independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For

 

 

SPDR SERIES TRUST

 

Security	78464A870	Meeting Type	Special
Ticker Symbol	XBI	Meeting Date	20-Oct-2022
Record Date	20-Jul-2022

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Clare S. Richer				For		For
		2	Sandra G. Sponem				For		For
		3	Kristi L. Rowsell				For		For
		4	Gunjan Chauhan				For		For
		5	Carolyn M. Clancy				For		For

 

STRYKER CORPORATION

 

Security	863667101	Meeting Type	Annual
Ticker Symbol	SYK	Meeting Date	10-May-2023
Record Date	13-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Mary K. Brainerd		Management		For		For
1b.		Election of Director: Giovanni Caforio, M.D.		Management		For		For
1c.		Election of Director: Srikant M. Datar, Ph.D.		Management		For		For
1d.		Election of Director: Allan C. Golston		Management		For		For
1e.		Election of Director: Kevin A. Lobo (Chair of the Board, Chief Executive Officer and President)		Management		For		For
1f.		Election of Director: Sherilyn S. McCoy (Lead Independent Director)		Management		For		For
1g.		Election of Director: Andrew K. Silvernail		Management		For		For
1h.		Election of Director: Lisa M. Skeete Tatum		Management		For		For
1i.		Election of Director: Ronda E. Stryker		Management		For		For
1j.		Election of Director: Rajeev Suri		Management		For		For
2.		Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for 2023.		Management		For		For
3.		Advisory Vote to Approve Named Executive Officer Compensation.		Management		For		For
4.		Advisory Vote on the Frequency of Future Advisory Votes on Named Executive Officer Compensation.		Management		1 Year		For
5.		Shareholder Proposal on Political Disclosure.		Shareholder		Against		For

 

 

SUTRO BIOPHARMA, INC.

 

Security	869367102	Meeting Type	Annual
Ticker Symbol	STRO	Meeting Date	08-Jun-2023
Record Date	20-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	William J. Newell				For		For
		2	Connie Matsui				For		For
		3	James Panek				For		For
2.		To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.			Management		For		For
3.		To approve, on a non-binding, advisory basis, the compensation of our named executive officers.			Management		For		For
4.		To approve the amendment and restatement of our restated certificate of incorporation to permit the exculpation of our officers from personal liability for certain breaches of the duty of care.			Management		For		For

 

SYNDAX PHARMACEUTICALS, INC

 

Security	87164F105	Meeting Type	Annual
Ticker Symbol	SNDX	Meeting Date	17-May-2023
Record Date	22-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Director: Pierre Legault		Management		For		For
1.2		Election of Director: Michael A. Metzger		Management		For		For
2.		To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the 2023 proxy statement.		Management		For		For
3.		To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.		Management		For		For
4.		To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.		Management		For		For

 

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

 

Security	881624209	Meeting Type	Annual
Ticker Symbol	TEVA	Meeting Date	15-Jun-2023
Record Date	10-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1A.		Election of Director: Dr. Sol J. Barer		Management		For		For
1B.		Election of Director: M. Braverman-Blumenstyk		Management		For		For
1C.		Election of Director: Janet S. Vergis		Management		For		For
2.		To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers.		Management		For		For
3.		To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2024 annual meeting of shareholders.		Management		For		For

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

 

Security	881624209	Meeting Type	Annual
Ticker Symbol	TEVA	Meeting Date	15-Jun-2023
Record Date	08-May-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1A.		Election of Director: Dr. Sol J. Barer		Management		For		For
1B.		Election of Director: M. Braverman-Blumenstyk		Management		For		For
1C.		Election of Director: Janet S. Vergis		Management		For		For
2.		To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers.		Management		For		For
3.		To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2024 annual meeting of shareholders.		Management		For		For

 

 

THE CIGNA GROUP

 

Security	125523100	Meeting Type	Annual
Ticker Symbol	CI	Meeting Date	26-Apr-2023
Record Date	07-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: David M. Cordani		Management		For		For
1b.		Election of Director: William J. DeLaney		Management		For		For
1c.		Election of Director: Eric J. Foss		Management		For		For
1d.		Election of Director: Retired Maj. Gen. Elder Granger, M.D.		Management		For		For
1e.		Election of Director: Neesha Hathi		Management		For		For
1f.		Election of Director: George Kurian		Management		For		For
1g.		Election of Director: Kathleen M. Mazzarella		Management		For		For
1h.		Election of Director: Mark B. McClellan, M.D., Ph.D.		Management		For		For
1i.		Election of Director: Kimberly A. Ross		Management		For		For
1j.		Election of Director: Eric C. Wiseman		Management		For		For
1k.		Election of Director: Donna F. Zarcone		Management		For		For
2.		Advisory approval of The Cigna Group's executive compensation		Management		For		For
3.		Advisory approval of the frequency of future advisory votes on executive compensation		Management		1 Year		For
4.		Ratification of the appointment of PricewaterhouseCoopers LLP as The Cigna Group's independent registered public accounting firm for 2023		Management		For		For
5.		Approval of an amendment to our Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted pursuant to recent amendments to the Delaware General Corporation Law		Management		For		For
6.		Shareholder proposal - Special shareholder meeting improvement		Shareholder		Against		For
7.		Shareholder proposal - Political contributions report		Shareholder		Against		For

 

 

THERMO FISHER SCIENTIFIC INC.

 

Security	883556102	Meeting Type	Annual
Ticker Symbol	TMO	Meeting Date	24-May-2023
Record Date	27-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Marc N. Casper		Management		For		For
1b.		Election of Director: Nelson J. Chai		Management		For		For
1c.		Election of Director: Ruby R. Chandy		Management		For		For
1d.		Election of Director: C. Martin Harris		Management		For		For
1e.		Election of Director: Tyler Jacks		Management		For		For
1f.		Election of Director: R. Alexandra Keith		Management		For		For
1g.		Election of Director: James C. Mullen		Management		For		For
1h.		Election of Director: Lars R. Sørensen		Management		For		For
1i.		Election of Director: Debora L. Spar		Management		For		For
1j.		Election of Director: Scott M. Sperling		Management		For		For
1k.		Election of Director: Dion J. Weisler		Management		For		For
2.		An advisory vote to approve named executive officer compensation.		Management		For		For
3.		An advisory vote on the frequency of future named executive officer advisory votes.		Management		1 Year		For
4.		Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2023.		Management		For		For
5.		Approval of the Company's Amended and Restated 2013 Stock Incentive Plan.		Management		For		For
6.		Approval of the Company's 2023 Global Employee Stock Purchase Plan.		Management		For		For

 

THESEUS PHARMACEUTICALS, INC.

 

Security	88369M101	Meeting Type	Annual
Ticker Symbol	THRX	Meeting Date	09-Jun-2023
Record Date	13-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Carl Gordon				For		For
		2	Michael Rome				For		For
2.		To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.			Management		For		For
3.		To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law.			Management		For		For

 

 

TRAVERE THERAPEUTICS INC.

 

Security	89422G107	Meeting Type	Annual
Ticker Symbol	TVTX	Meeting Date	17-May-2023
Record Date	21-Mar-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Roy Baynes				For		For
		2	Suzanne Bruhn				For		For
		3	Timothy Coughlin				For		For
		4	Eric Dube				For		For
		5	Gary Lyons				For		For
		6	Jeffrey Meckler				For		For
		7	John Orwin				For		For
		8	Sandra Poole				For		For
		9	Ron Squarer				For		For
		10	Ruth Williams-Brinkley				For		For
2.		To approve the Company's 2018 Equity Incentive Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000 shares.			Management		For		For
3.		To approve, on an advisory basis, the compensation of the Company's named executive officers.			Management		For		For
4.		To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.			Management		For		For

 

TSCAN THERAPEUTICS, INC.

 

Security	89854M101	Meeting Type	Annual
Ticker Symbol	TCRX	Meeting Date	13-Jun-2023
Record Date	17-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Katina Dorton, JD, MBA				For		For
2.		To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023			Management		For		For
3.		To approve an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan to increase the number of shares of voting common stock authorized for issuance under the plan by 7,500,000 shares			Management		For		For

 

 

ULTRAGENYX PHARMACEUTICAL INC.

 

Security	90400D108	Meeting Type	Annual
Ticker Symbol	RARE	Meeting Date	07-Jun-2023
Record Date	17-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Emil D. Kakkis, M.D., Ph.D.		Management		For		For
1b.		Election of Director: Shehnaaz Suliman, M.D.		Management		For		For
1c.		Election of Director: Daniel G. Welch		Management		For		For
2.		Approval of the 2023 Incentive Plan.		Management		For		For
3.		Approval of the Amended & Restated Employee Stock Purchase Plan.		Management		For		For
4.		Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.		Management		For		For
5.		Advisory (non-binding) vote to approve the compensation of our named executive officers.		Management		For		For

 

UNIQURE N.V.

 

Security	N90064101	Meeting Type	Annual
Ticker Symbol	QURE	Meeting Date	13-Jun-2023
Record Date	17-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Resolution to adopt the 2022 Dutch statutory annual accounts and treatment of the results.		Management		For		For
2.		Resolution to discharge liability of the members of the Board.		Management		For		For
3.		Reappointment of Madhavan Balachandran as non-executive director.		Management		For		For
4.		Reappointment of Jack Kaye as non-executive director.		Management		For		For
5.		Reappointment of Leonard Post as non-executive director.		Management		For		For
6.		Reappointment of Jeremy Springhorn as non-executive director.		Management		For		For
7.		Resolution to renew the designation of the Board as the competent body to issue Ordinary Shares and options.		Management		For		For
8.		Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares.		Management		For		For
9.		Resolution to reauthorize the Board to repurchase Ordinary Shares.		Management		For		For
10.		Resolution to appoint KPMG as external auditors of the Company for the financial year 2023.		Management		For		For
11.		Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company.		Management		For		For
12.		Resolution to approve the amendment and restatement of the Company's 2014 Share Incentive Plan.		Management		For		For

 

 

UNIQURE N.V.

 

Security	N90064101	Meeting Type	Annual
Ticker Symbol	QURE	Meeting Date	13-Jun-2023
Record Date	16-May-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Resolution to adopt the 2022 Dutch statutory annual accounts and treatment of the results.		Management		For		For
2.		Resolution to discharge liability of the members of the Board.		Management		For		For
3.		Reappointment of Madhavan Balachandran as non-executive director.		Management		For		For
4.		Reappointment of Jack Kaye as non-executive director.		Management		For		For
5.		Reappointment of Leonard Post as non-executive director.		Management		For		For
6.		Reappointment of Jeremy Springhorn as non-executive director.		Management		For		For
7.		Resolution to renew the designation of the Board as the competent body to issue Ordinary Shares and options.		Management		For		For
8.		Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares.		Management		For		For
9.		Resolution to reauthorize the Board to repurchase Ordinary Shares.		Management		For		For
10.		Resolution to appoint KPMG as external auditors of the Company for the financial year 2023.		Management		For		For
11.		Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company.		Management		For		For
12.		Resolution to approve the amendment and restatement of the Company's 2014 Share Incentive Plan.		Management		For		For

 

 

UNITED THERAPEUTICS CORPORATION

 

Security	91307C102	Meeting Type	Annual
Ticker Symbol	UTHR	Meeting Date	26-Jun-2023
Record Date	27-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Christopher Causey		Management		For		For
1b.		Election of Director: Raymond Dwek		Management		For		For
1c.		Election of Director: Richard Giltner		Management		For		For
1d.		Election of Director: Katherine Klein		Management		For		For
1e.		Election of Director: Ray Kurzweil		Management		For		For
1f.		Election of Director: Linda Maxwell		Management		For		For
1g.		Election of Director: Nilda Mesa		Management		For		For
1h.		Election of Director: Judy Olian		Management		For		For
1i.		Election of Director: Christopher Patusky		Management		For		For
1j.		Election of Director: Martine Rothblatt		Management		For		For
1k.		Election of Director: Louis Sullivan		Management		For		For
1l.		Election of Director: Tommy Thompson		Management		For		For
2.		Advisory resolution to approve executive compensation.		Management		For		For
3.		Advisory vote on the frequency of future advisory votes on executive compensation.		Management		1 Year		For
4.		Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan.		Management		For		For
5.		Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2023.		Management		For		For

 

UNITEDHEALTH GROUP INCORPORATED

 

Security	91324P102	Meeting Type	Annual
Ticker Symbol	UNH	Meeting Date	05-Jun-2023
Record Date	10-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Timothy Flynn		Management		For		For
1b.		Election of Director: Paul Garcia		Management		For		For
1c.		Election of Director: Kristen Gil		Management		For		For
1d.		Election of Director: Stephen Hemsley		Management		For		For
1e.		Election of Director: Michele Hooper		Management		For		For
1f.		Election of Director: F. William McNabb III		Management		For		For
1g.		Election of Director: Valerie Montgomery Rice, M.D.		Management		For		For
1h.		Election of Director: John Noseworthy, M.D.		Management		For		For
1i.		Election of Director: Andrew Witty		Management		For		For
2.		Advisory approval of the Company's executive compensation.		Management		For		For
3.		Advisory approval of the frequency of holding future say-on-pay votes.		Management		1 Year		For
4.		Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023.		Management		For		For
5.		If properly presented at the 2023 Annual Meeting of Shareholders, the shareholder proposal seeking a third-party racial equity audit.		Shareholder		Against		For
6.		If properly presented at the 2023 Annual Meeting of Shareholders, the shareholder proposal requiring a political contributions congruency report.		Shareholder		Against		For
7.		If properly presented at the 2023 Annual Meeting of Shareholders, the shareholder proposal seeking shareholder ratification of termination pay.		Shareholder		Against		For

 

 

VAXCYTE, INC.

 

Security	92243G108	Meeting Type	Annual
Ticker Symbol	PCVX	Meeting Date	13-Jun-2023
Record Date	17-Apr-2023

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Halley Gilbert, J.D.				For		For
		2	Michael E Kamarck Ph.D.				For		For
		3	Grant E Pickering M.B.A				For		For
2.		Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.			Management		For		For
3.		Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.			Management		For		For

 

VECTIVBIO HOLDING AG

 

Security	H9060V101	Meeting Type	Special
Ticker Symbol	VECT	Meeting Date	09-Dec-2022
Record Date	31-Oct-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Wouter Joustra - The Board of Directors proposes to elect Wouter Joustra as a new member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting of the Company.		Management		For		For

 

 

VECTIVBIO HOLDING AG

 

Security	H9060V101	Meeting Type	Annual
Ticker Symbol	VECT	Meeting Date	01-Jun-2023
Record Date	02-May-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Approval of the 2022 Statutory Financial Statements and Consolidated Financial Statements - The Board of Directors proposes that the Statutory Financial Statements and the Consolidated Financial Statements for the financial year 2022 be approved.		Management		For		For
1.2		Advisory Vote on the 2022 Compensation Report - The Board of Directors proposes that the 2022 Compensation Report be endorsed in a non-binding advisory vote.		Management		For		For
2		Appropriation of 2022 Financial Results - The Board of Directors proposes that the loss of the Company be carried forward as follows: Loss carried forward from the financial year 2021 CHF -28,435,076 Loss for the financial year 2022 CHF -36,211,404 Loss to be carried forward CHF -64,646,480.		Management		For		For
3		Discharge of the Board of Directors and of the Executive Committee - The Board of Directors proposes that all members of the Board of Directors and of the Executive Committee be discharged from liability for their activities during the financial year 2022.		Management		For		For
4.1		Re-election of Thomas Woiwode (as Chairman and member of the Board of Directors) - The Board of Directors proposes to re-elect Thomas Woiwode as Chairman and member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.		Management		For		For
4.2		Re-election of Sandip Kapadia - The Board of Directors proposes to re-elect Sandip Kapadia as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.		Management		For		For
4.3		Re-election of Paul Rutherford Carter - The Board of Directors proposes to re-elect Paul Rutherford Carter as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.		Management		For		For
4.4		Re-election of Luca Santarelli - The Board of Directors proposes to re-elect Luca Santarelli as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.		Management		For		For
4.5		Re-election of Hans Schikan - The Board of Directors proposes to re-elect Hans Schikan as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.		Management		For		For
4.6		Re-election of Murray Willis Stewart - The Board of Directors proposes to re-elect Murray Willis Stewart as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.		Management		For		For
4.7		Re-election of Wouter Joustra - The Board of Directors proposes to re-elect Wouter Joustra as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting.		Management		For		For
5.1		Re-election of Paul Rutherford Carter - The Board of Directors proposes to re-elect Paul Rutherford Carter as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting.		Management		For		For
5.2		Re-election of Murray Willis Stewart - The Board of Directors proposes to re-elect Murray Willis Stewart as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting.		Management		For		For
5.3		Re-election of Thomas Woiwode - The Board of Directors proposes to re-elect Thomas Woiwode as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting.		Management		For		For
6		Re-election of the Statutory Auditors - The Board of Directors proposes that Ernst & Young AG, in Basel, Switzerland, be re-elected as the Company's statutory auditors for the financial year 2023.		Management		For		For
7		Re-election of the Independent Proxy - The Board of Directors proposes that Buis Bürgi AG, Zurich, Switzerland, be re-elected as independent proxy for a term of office until completion of the 2024 Annual General Meeting.		Management		For		For
8.1		Approval of the Maximum Aggregate Amount of Compensation of the Board of Directors - The Board of Directors proposes that a maximum aggregate amount of compensation of the Board of Directors for the period from the 2023 Annual General Meeting to the 2024 Annual General Meeting of CHF 2,200,000 be approved.		Management		For		For
8.2		Approval of the Maximum Aggregate Amount of Compensation of the Executive Committee - The Board of Directors proposes that a maximum aggregate amount of compensation of the Executive Committee for the financial year 2024 of CHF 18,500,000 be approved.		Management		For		For
9		Introduction of a Capital Range - The Board of Directors proposes to cancel the existing authorized share capital pursuant to article 3a of the Articles of Association and to replace it with a capital range ranging from CHF 3,369,589.50 (lower limit) to CHF 5,054,384.25 (upper limit) as set forth in the invitation to the 2023 Annual General Meeting.		Management		For		For
10		Increase of the Conditional Share Capital for Participation Programs - The Board of Directors proposes (i) that the Company's conditional share capital for participation programs be increased by CHF 692,576.75 to the maximum amount of CHF 1,233,908.75, allowing the issuance of up to 24,678,175 registered shares with a par value of CHF 0.05 each, and, accordingly, to amend article 3b (Conditional Share Capital for Participation Programs), paragraph 1, of the Articles ...(due to space limits, see proxy material for full proposal).		Management		Against		Against
11a		Amendments to the Articles of Association - Share Certificates and Intermediated Securities, Share Register, Restrictions on Registration, Nominees - The Board of Directors proposes to amend articles 4 and 5 of the Articles of Association as set forth in the invitation to the 2023 Annual General Meeting.		Management		For		For
11b		Amendments to the Articles of Association - Shareholder Rights, General Meeting of Shareholders, Notices and Communications - The Board of Directors proposes to amend articles 7, 8, 9, 10, 13, 24 and 34 of the Articles of Association as set forth in the invitation to the 2023 Annual General Meeting.		Management		For		For
11c		Amendments to the Articles of Association - Board of Directors, Compensation of the Executive Committee, Mandates Outside the Company - The Board of Directors proposes to amend articles 18, 19, 26, 27 and 29 of the Articles of Association as set forth in the invitation to the 2023 Annual General Meeting.		Management		For		For
11d		Amendments to the Articles of Association - Jurisdiction Clause - The Board of Directors proposes to introduce a new article 35 to our Articles of Association as set forth in the invitation to the 2023 Annual General Meeting.		Management		For		For

 

 

VECTIVBIO HOLDING AG

 

Security	H9060V101	Meeting Type	Special
Ticker Symbol	VECT	Meeting Date	26-Jun-2023
Record Date	22-May-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		Removal of the Restrictions on Registration and Exercise of Voting Rights (Conditional Resolution) - The Board of Directors proposes to amend article 5 paras. 2, 4, 5 and 6 and article 12 paras. 1 and 2 of the Articles of Association as set forth in the invitation to the Extraordinary General Meeting, provided that these amendments shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).		Management		For		For
2.1		Election of Andrew Davis (as Chairperson and member of the Board of Directors) - The Board of Directors proposes to elect Andrew Davis as Chairperson and member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).		Management		For		For
2.2		Election of John Minardo (as member of the Board of Directors) - The Board of Directors proposes to elect John Minardo as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).		Management		For		For
2.3		Election of Sravan Emany (as member of the Board of Directors) - The Board of Directors proposes to elect Sravan Emany as member of the Board of Directors for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).		Management		For		For
3.1		Election of Andrew Davis - The Board of Directors proposes to elect Andrew Davis as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).		Management		For		For
3.2		Election of John Minardo - The Board of Directors proposes to elect John Minardo as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).		Management		For		For
3.3		Election of Sravan Emany - The Board of Directors proposes to elect Sravan Emany as member of the Compensation Committee for a term of office until completion of the 2024 Annual General Meeting, provided that this election shall be subject to, and only become effective upon, the Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting).		Management		For		For
4.		Delisting of the Company's Shares (Conditional Resolution) - The Board of Directors proposes to approve the delisting of the ordinary shares of the Company from Nasdaq, subject to (i) Completion of the Tender Offer (as defined in the invitation to the Extraordinary General Meeting) and (ii) satisfaction of the requirements under the listing rules of the Nasdaq Stock Market, LLC.		Management		For		For

 

 

VERTEX PHARMACEUTICALS INCORPORATED

 

Security	92532F100	Meeting Type	Annual
Ticker Symbol	VRTX	Meeting Date	17-May-2023
Record Date	23-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.1		Election of Director: Sangeeta Bhatia		Management		For		For
1.2		Election of Director: Lloyd Carney		Management		For		For
1.3		Election of Director: Alan Garber		Management		For		For
1.4		Election of Director: Terrence Kearney		Management		For		For
1.5		Election of Director: Reshma Kewalramani		Management		For		For
1.6		Election of Director: Jeffrey Leiden		Management		For		For
1.7		Election of Director: Diana McKenzie		Management		For		For
1.8		Election of Director: Bruce Sachs		Management		For		For
1.9		Election of Director: Suketu Upadhyay		Management		For		For
2.		Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2023.		Management		For		For
3.		Advisory vote to approve named executive office compensation.		Management		For		For
4.		Advisory vote on the frequency of future advisory votes on executive compensation.		Management		1 Year		For

 

VYNE THERAPEUTICS INC.

 

Security	92941V209	Meeting Type	Annual
Ticker Symbol	VYNE	Meeting Date	10-Aug-2022
Record Date	14-Jun-2022

 

Item		Proposal			Proposed by		Vote		For/Against Management
1.		DIRECTOR			Management
		1	Steven Basta				For		For
		2	Anthony Bruno				For		For
		3	Elisabeth Sandoval				For		For
2.		To ratify the selection by the Audit Committee of the Company's Board of Directors of Baker Tilly US, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.			Management		For		For
3.		To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from 1-for-5 shares up to a ratio of 1-for-15 shares, which ratio will be selected by the Company's Board of Directors and set forth in a public announcement.			Management		For		For
4.		To approve the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 3.			Management		For		For

 

 

VYNE THERAPEUTICS INC.

 

Security	92941V209	Meeting Type	Special
Ticker Symbol	VYNE	Meeting Date	12-Jan-2023
Record Date	16-Nov-2022

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from 1-for-10 shares up to a ratio of 1-for-25 shares, which ratio will be selected by the Company's Board of Directors and set forth in a public announcement.		Management		For		For
2.		To approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1.		Management		For		For

 

WEST PHARMACEUTICAL SERVICES, INC.

 

Security	955306105	Meeting Type	Annual
Ticker Symbol	WST	Meeting Date	25-Apr-2023
Record Date	03-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Mark A. Buthman		Management		For		For
1b.		Election of Director: William F. Feehery		Management		For		For
1c.		Election of Director: Robert F. Friel		Management		For		For
1d.		Election of Director: Eric M. Green		Management		For		For
1e.		Election of Director: Thomas W. Hofmann		Management		For		For
1f.		Election of Director: Molly E. Joseph		Management		For		For
1g.		Election of Director: Deborah L. V. Keller		Management		For		For
1h.		Election of Director: Myla P. Lai-Goldman		Management		For		For
1i.		Election of Director: Stephen H. Lockhart		Management		For		For
1j.		Election of Director: Douglas A. Michels		Management		For		For
1k.		Election of Director: Paolo Pucci		Management		For		For
2.		Advisory vote to approve named executive officer compensation.		Management		For		For
3.		To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023.		Management		For		For
4.		Advisory vote on the frequency of an advisory vote on executive compensation.		Management		1 Year		For
5.		Shareholder proposal regarding Fair Elections.		Shareholder		For		Against

 

 

ZAI LAB LTD

 

Security	98887Q104	Meeting Type	Annual
Ticker Symbol	ZLAB	Meeting Date	20-Jun-2023
Record Date	20-Apr-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1.		THAT, Samantha (Ying) Du is hereby re-elected to serve as a director until the 2024 annual general meeting		Management		For		For
2.		THAT, Kai-Xian Chen is hereby re-elected to serve as a director until the 2024 annual general meeting		Management		For		For
3.		THAT, John D. Diekman is hereby re-elected to serve as a director until the 2024 annual general meeting		Management		For		For
4.		THAT, Richard Gaynor is hereby re-elected to serve as a director until the 2024 annual general meeting		Management		For		For
5.		THAT, Nisa Leung is hereby re-elected to serve as a director until the 2024 annual general meeting		Management		For		For
6.		THAT, William Lis is hereby re-elected to serve as a director until the 2024 annual general meeting		Management		For		For
7.		THAT, Scott Morrison is hereby re-elected to serve as a director until the 2024 annual general meeting		Management		For		For
8.		THAT, Leon O. Moulder, Jr. is hereby re-elected to serve as a director until the 2024 annual general meeting		Management		For		For
9.		THAT, Michel Vounatsos is hereby elected to serve as a director until the 2024 annual general meeting		Management		For		For
10.		THAT, Peter Wirth is hereby re-elected to serve as a director until the 2024 annual general meeting		Management		For		For
11.		THAT, the appointment of KPMG LLP and KPMG as the Company's independent registered public accounting firms and auditors to audit the Company's consolidated financial statements to be filed with the U.S. Securities and Exchange Commission and The Stock Exchange of Hong Kong Limited for the year ending December 31, 2023, respectively, is hereby approved.		Management		For		For
12.		THAT, the authority of the Board of Directors to fix the auditor compensation for 2023, is hereby approved.		Management		For		For
13.		THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement, is hereby approved.		Management		For		For
14.		THAT, within the parameters of Rule 13.36 of the HK Listing Rules, the granting of a general mandate to the Board of Directors to allot and issue ordinary shares and/or American Depositary Shares of up to 20% of the total number of issued ordinary shares of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company, is hereby approved.		Management		For		For
15.		THAT, if Ordinary Resolution 14 is not approved, within the parameters of Rule 13.36 of the HK Listing Rules, the granting of a general mandate to the Board of Directors to allot and issue ordinary shares and/or American Depositary Shares of up to 10% of the total number of issued ordinary shares of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company, is hereby approved.		Management		For		For

 

 

ZOETIS INC.

 

Security	98978V103	Meeting Type	Annual
Ticker Symbol	ZTS	Meeting Date	18-May-2023
Record Date	24-Mar-2023

 

Item		Proposal		Proposed by		Vote		For/Against Management
1a.		Election of Director: Paul M. Bisaro		Management		For		For
1b.		Election of Director: Vanessa Broadhurst		Management		For		For
1c.		Election of Director: Frank A. D'Amelio		Management		For		For
1d.		Election of Director: Michael B. McCallister		Management		For		For
1e.		Election of Director: Gregory Norden		Management		For		For
1f.		Election of Director: Louise M. Parent		Management		For		For
1g.		Election of Director: Kristin C. Peck		Management		For		For
1h.		Election of Director: Robert W. Scully		Management		For		For
2.		Advisory vote to approve our executive compensation.		Management		For		For
3.		Ratification of appointment of KPMG LLP as our independent registered public accounting firm for 2023.		Management		For		For
4.		Approval of an amendment to our Restated Certificate of Incorporation to create a right to call a special meeting.		Management		For		For
5.		Shareholder proposal regarding ability to call a special meeting.		Shareholder		Against		For

 

 

SIGNATURES

 

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

(Registrant)			Tekla Healthcare Investors
By (Signature and Title)*
			/s/ Daniel R. Omstead
			(Daniel R. Omstead, President)
Date			8/4/23

 

*Print the name and title of each signing officer under his or her signature.

 

---